GNC 10-Q 11 May 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2020	May 06, 2020
Cover [Abstract]
Document Quarterly Report	true
Title of 12(b) Security	Class A common stock, par value $0.001 per share
Entity Incorporation, State or Country Code	DE
Entity Registrant Name	GNC Holdings, Inc.
Entity Central Index Key	0001502034
Document Type	10-Q
Entity File Number	001-35113
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		84,607,231
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Tax Identification Number	20-8536244
Entity Address, Address Line One	300 Sixth Avenue
Entity Address, Postal Zip Code	15222
Trading Symbol	GNC
Security Exchange Name	NYSE
City Area Code	412
Local Phone Number	288-4600
Document Transition Report	false
Entity Address, City or Town	Pittsburgh,
Entity Address, State or Province	PA

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 137,444	$ 117,046
Receivables, net of allowance of $27,390 and $22,648, respectively (Note 2)	83,932	101,234
Receivables due from related parties (Note 8)	6,547	8,946
Inventory (Note 4)	367,402	387,655
Prepaid and other current assets	34,348	24,880
Total current assets	629,673	639,761
Long-term assets:
Goodwill (Note 6)	73,552	79,109
Brand name (Note 6)	189,000	300,720
Other intangible assets, net (Note 6)	69,891	71,298
Property, plant and equipment, net (Note 5)	72,054	86,916
Right-of-use assets	305,788	350,579
Equity method investments (Note 8)	42,520	97,930
Deferred tax assets	12,389	0
Other long-term assets	21,090	24,274
Total long-term assets	786,284	1,010,826
Total assets	1,415,957	1,650,587
Current liabilities:
Accounts payable	143,535	150,742
Accounts payable due to related parties (Note 8)	21,136	11,720
Current portion of long-term debt (Note 7)	895,022	180,566
Current lease liabilities	106,704	112,005
Deferred revenue and other current liabilities	94,812	105,792
Total current liabilities	1,261,209	560,825
Long-term liabilities:
Long-term debt (Note 7)	0	681,999
Deferred income taxes	0	31,586
Lease liabilities	305,194	330,510
Other long-term liabilities	40,549	41,535
Total long-term liabilities	345,743	1,085,630
Total liabilities	1,606,952	1,646,455
Contingencies (Note 10)
Mezzanine equity:
Convertible preferred stock (Note 11)	211,395	211,395
Stockholders’ deficit:
Common stock	131	131
Additional paid-in capital	1,013,394	1,012,076
Retained earnings	318,519	518,605
Treasury stock, at cost	(1,725,349)	(1,725,349)
Accumulated other comprehensive loss	(9,085)	(12,726)
Total stockholders’ deficit	(402,390)	(207,263)
Total liabilities, mezzanine equity and stockholders’ deficit	$ 1,415,957	$ 1,650,587

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 27,390	$ 22,648

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenue (Note 3)	$ 472,581	$ 564,764
Cost of sales, including warehousing, distribution and occupancy	335,865	361,673
Gross profit	136,716	203,091
Selling, general, and administrative	144,542	148,303
Long-lived asset impairments and other store closing costs	157,515	0
Loss on net asset exchange for the formation of the joint ventures (Note 8)	1,655	19,514
Other income, net	(962)	(208)
Operating (loss) income	(166,034)	35,482
Interest expense, net (Note 7)	47,444	32,956
Loss on forward contracts for the issuance of convertible preferred stock	0	16,787
Loss before income from equity method investments and income taxes	(213,478)	(14,261)
Income tax (benefit) expense (Note 14)	(53,035)	1,956
Loss before income from equity method investments	(160,443)	(16,217)
(Loss) income from equity method investments (Note 8)	(39,643)	955
Net loss	$ (200,086)	$ (15,262)
Loss per share (Note 12):
Basic (in dollars per share)	$ (2.45)	$ (0.23)
Diluted (in dollars per share)	$ (2.45)	$ (0.23)
Weighted average common shares outstanding (Note 12):
Basic weighted-average shares (in shares)	83,897	83,510
Diluted weighted-average shares (in shares)	83,897	83,510

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net loss		$ (200,086)	$ (15,262)
Other comprehensive gain (loss):
Periodic revaluation of interest rate swap, net of tax	[1]	(3,542)	(1,464)
Reclassification adjustment for interest recognized in Consolidated Statement of Operations, net of tax	[2]	871	236
Net change in unrecognized loss on interest rate swaps, net of tax		(2,671)	(1,228)
Deferred loss recognized on interest rate swap, net of $3.4 million tax expense		7,459	0
Foreign currency translation (loss) gain		(1,147)	438
Other comprehensive gain (loss)		3,641	(790)
Comprehensive loss		$ (196,445)	$ (16,052)
[1]	Net of tax benefit of $1.6 million and $0.7 million, respectively, for the three months ended March 31, 2020 and 2019.
[2]	Net of tax expense of $0.4 million and $0.1 million, respectively, for the three months ended March 31, 2020 and 2019.

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Tax expense (benefit) before reclassification	$ (1.6)	$ (0.7)
Tax expense from reclassification	0.4	$ 0.1
Tax expense from deferred loss	$ 3.4

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Treasury Stock	Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2018		83,886
Beginning balance at Dec. 31, 2018	$ (114,310)	$ 130	$ (1,725,349)	$ 1,007,827	$ 613,637	$ (10,555)
Increase (Decrease) in Stockholders' Equity
Comprehensive income	(16,052)				(15,262)	(790)
Restricted stock awards (in shares)		121
Restricted stock awards	0
Minimum tax withholding requirements (in shares)		(41)
Minimum tax withholding requirements	(120)			(120)
Stock-based compensation	1,334			1,334
Ending balance (in shares) at Mar. 31, 2019		83,966
Ending balance at Mar. 31, 2019	(189,084)	$ 130	(1,725,349)	1,009,041	538,439	(11,345)
Beginning balance (in shares) at Dec. 31, 2019		84,564
Beginning balance at Dec. 31, 2019	(207,263)	$ 131	(1,725,349)	1,012,076	518,605	(12,726)
Increase (Decrease) in Stockholders' Equity
Comprehensive income	(196,445)				(200,086)	3,641
Restricted stock awards (in shares)		68
Restricted stock awards	0
Minimum tax withholding requirements (in shares)		(24)
Minimum tax withholding requirements	(54)			(54)
Stock-based compensation	1,372			1,372
Ending balance (in shares) at Mar. 31, 2020		84,608
Ending balance at Mar. 31, 2020	$ (402,390)	$ 131	$ (1,725,349)	$ 1,013,394	$ 318,519	$ (9,085)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2020		Mar. 31, 2019
Cash flows from operating activities:
Net loss		$ (200,086)		$ (15,262)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization expense		7,858		10,190
Loss (income) from equity method investments		39,643		(955)
Amortization of debt costs		16,814		7,988
Stock-based compensation		1,372		1,334
Long-lived asset impairments and other store closing costs		157,515		0
Loss on forward contracts for the issuance of convertible preferred stock		0		16,787
Loss on net asset exchange for the formation of the joint ventures		1,655		19,514
Interest expense recognized on interest rate swap		10,810		0
Deferred income tax benefit		(47,677)		(5,064)
Other		(2,107)		(21)
Changes in assets and liabilities:
Decrease (increase) in receivables		17,824		(12,567)
Decrease (increase) in inventory		17,578		(6,886)
Increase in prepaid and other current assets		(8,401)		(3,658)
Increase in accounts payable		3,346		57,722
Decrease in deferred revenue and accrued liabilities		(22,686)		4,437
Decrease in net lease liabilities		(7,035)		(8,485)
Other operating activities		1,492		3,637
Net cash (used in) provided by operating activities		(12,085)		68,711
Cash flows from investing activities:
Capital expenditures		(3,858)		(3,017)
Refranchising proceeds, net of store acquisition costs		180		667
Proceeds from net asset exchange		18,211		101,000
Capital contribution to the newly formed joint ventures		0		(13,079)
Net cash provided by investing activities		14,533		85,571
Cash flows from financing activities:
Borrowings under revolving credit facility		30,000		22,000
Payments on revolving credit facility		0		(22,000)
Proceeds from the issuance of convertible preferred stock		0		199,950
Original issuance discount and revolving credit facility fees		0		(10,365)
Fees associated with the issuance of convertible preferred stock		0		(12,564)
Minimum tax withholding requirements		(54)		(120)
Net cash provided by (used) in financing activities		18,227		(84,411)
Effect of exchange rate changes on cash and cash equivalents		(277)		22
Net increase in cash and cash equivalents		20,398		69,893
Beginning balance, cash and cash equivalents		117,046		67,224
Ending balance, cash and cash equivalents		137,444		137,117
Non-cash investing activities:
Net assets contributed to the joint ventures (Note 8)	[1]	0	[2]	202,487
Tranche B-1
Cash flows from financing activities:
Payments on term loan facility		0		(147,312)
Tranche B-2
Cash flows from financing activities:
Payments on term loan facility		$ (11,719)		$ (114,000)
[1]	Capital expenditures included in current liabilities were not material during the three months ended March, 31, 2020 and March 31, 2019, respectively.
[2]	Net of tax expense of $0.4 million and $0.1 million, respectively, for the three months ended March 31, 2020 and 2019.

NATURE OF BUSINESS

NATURE OF BUSINESS	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS	NATURE OF BUSINESS GNC Holdings, Inc., a Delaware corporation (“Holdings,” and collectively with its subsidiaries and, unless the context requires otherwise, its and their respective predecessors, the “Company”), is a global health and wellness brand with a diversified, omni-channel business. The Company's assortment of performance and nutritional supplements, vitamins, herbs and greens, health and beauty, food and drink and other general merchandise features innovative private-label products as well as nationally recognized third-party brands, many of which are exclusive to GNC. The Company's operations consist of three reportable segments, U.S. and Canada, International, and Manufacturing / Wholesale (refer to Note 13, "Segments" for more information). Corporate retail store operations are located in the United States, Canada, Puerto Rico, Ireland and, prior to the joint venture transaction with Harbin Pharmaceutical Group Co., Ltd ("Harbin") in February 2019, China. Franchise locations exist in the United States and approximately 50 other countries. Products can also be purchased through GNC.com, Amazon.com and other marketplaces and select wholesale partners. Additionally, the Company licenses the use of its trademarks and trade names. Prior to the formation of the manufacturing joint venture with International Vitamin Corporation ("IVC") (the "Manufacturing JV") in March 2019, the Company purchased raw materials, manufactured products and sold the finished products through its reportable segments. Refer to Note 8. "Equity Method Investments" for more information of the Company's joint ventures. Going Concern As further discussed below, the Company has an accelerated maturity payment due on May 16, 2020 (the “Springing Maturity Date”) that it does not have the ability to pay. Since the Company has not refinanced the $738.7 million of Tranche B-2 Term Loan (the "Tranche B-2 Term Loan), FILO Term Loan (the "FILO Term Loan") and Revolving Credit Facility (the "Revolving Credit Facility") that will become due on the Springing Maturity Date, management has concluded there is substantial doubt regarding the Company's ability to continue as a going concern within one year from the issuance date of the Company’s Consolidated Financial Statements. Failure to complete a refinancing or other restructuring, obtain an extension of the Springing Maturity Date as defined in the Credit Agreements, reach an agreement with required lender groups under the Credit Agreements prior to May 16, 2020 or to reach an agreement with the Company's stakeholders on the terms of an out-of-court restructuring would have a material adverse effect on the Company's liquidity, financial condition and results of operations and may result in filing a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in order to implement a restructuring plan. As of March 31, 2020, the Company's outstanding indebtedness has been classified as current on the Company's Consolidated Balance Sheets. In addition, the Company accelerated the amortization of original issuance discount and deferred financing fees for the Tranche B-2 Term Loan, FILO Term Loan and the Revolving Credit Facility of $12.4 million to the Springing Maturity Date. The Company has continued to experience negative same store sales and declining gross profit. The Company has closed underperforming stores under its store optimization strategy and implemented cost reduction measures to help mitigate the effect of these declines and improve its financial position and liquidity. At March 31, 2020, the Company has substantial indebtedness including $156.4 million of outstanding indebtedness under the Notes issued under that certain Indenture dated as of August 10, 2015, among the Company, certain of its subsidiaries, and The Bank of New York Mellon Trust Company, N.A, maturing on August 15, 2020 (the "Notes") and $434.8 million of outstanding indebtedness under the Amended and Restated Term Loan Credit Agreement, dated as of February 28, 2018, among GNC Corporation, GNC Nutrition Centers, Inc., as Borrower, the lenders and agents parties thereto, and JPMorgan Chase Bank, N.A., as administrative agent (the “Tranche B-2 Term Loan Credit Agreement" and the term loan thereunder, the "Tranche B-2 Term Loan"). The Company made an excess cash flow payment of $25.9 million that was due in April 2020 which reduced the outstanding amount of the Tranche B-2 Term Loan. The Tranche B-2 Term Loan becomes due on the earlier to occur of (i) the maturity date of March 4, 2021 or (ii) May 16, 2020 if more than $50 million of the Notes are outstanding on such date. Each of the Revolving Credit Facility under the Credit Agreement, dated as of February 28, 2018, among GNC Corporation, GNC Nutritional Centers, Inc., as Administrative Borrower, certain of its subsidiaries, as subsidiary borrowers, the lenders and agents parties thereto, and JPMorgan Chase Bank, N.A., as administrative agent (the “ABL Credit Agreement,” and together with the Tranche B-2 Term Loan Credit Agreement, the "Credit Agreements") and the FILO Term Loan under the ABL Credit Agreement, which otherwise mature in August 2022 and December 2022 respectively, also include an accelerated maturity date of May 16, 2020 if more than $50 million of the Notes are outstanding on such date. The Company does not have the ability to reduce the outstanding balance on the Notes from $156.4 million to below $50 million with projected cash on hand and new borrowings under the Revolving Credit Facility, assuming such borrowings remain available. The outbreak of novel strain of coronavirus COVID-19 ("COVID-19") caused business disruption in the International segment beginning in January 2020. In late February 2020, the situation escalated as the scope of the COVID-19 outbreak worsened to directly impact areas outside of the Asia-Pacific region, with Europe and the United States recognizing outbreaks of COVID-19. As of March 31, 2020, the Company had temporarily closed approximately 30% of the U.S. and Canada company-owned and franchise stores as a result of the COVID-19 pandemic. There is significant uncertainty on the Company’s business going forward due to various global macroeconomic, operational and supply chain risks as a result of COVID-19. The Company was in compliance with the debt covenant reporting and compliance obligations under the Credit Agreements as of March 31, 2020. Management does not believe that the Company has the ability to comply with the financial covenants under the Senior Credit Facility Agreements over the next twelve months given the current circumstances stemming from the COVID-19 pandemic. The Company is in the process of reviewing a range of refinancing options to refinance the Company’s outstanding indebtedness. The Company has been working with an independent committee of the Board supported by independent financial and legal advisors to conduct its review and has had a series of discussions with financing sources in the United States and Asia. The Company will continue to explore all options to refinance and restructure its indebtedness. While the Company continues to work through a number of refinancing alternatives to address its upcoming debt maturities, the Company cannot make any assurances regarding the likelihood, certainty or exact timing of any alternatives. Reporting requirements under both the Tranche B-2 Term Loan and the Credit Agreement require the Company to provide annual audited financial statements accompanied by an opinion of an independent public accountant without a "going concern" or like qualification or exception, or qualification arising out of the scope of the audit (other than a “going concern” statement, explanatory note or like qualification or exception resulting solely from an upcoming maturity date under the Tranche B-2 Term Loan or the Notes). Management believes the Company satisfied this requirement in the 2019 Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the "SEC") on March 25, 2020 (the "2019 10-K"). If the lenders take a contrary position, (a) they could decide to instruct the administrative agent under the Senior Credit Agreements to deliver a written notice thereof to the borrower, and if the alleged default continued uncured for 30 days thereafter it would become an alleged event of default (unless waived by the lenders) and (b) the Company intends to contest such position and any action the lenders may attempt to take as a result thereof. If the lenders were to prevail in any such dispute, the required lenders could instruct the administrative agent to exercise remedies under the Senior Credit Agreements, including accelerating the maturity of the loans, terminating commitments under the revolving credit facility under the ABL Credit Agreement and requiring the posting of cash collateral in respect of outstanding letters of credit issued under the Revolving Credit Facility ($4.5 million at March 31, 2020). If this were to occur, management would enter into discussions with the lenders to waive the default or forebear from the exercise of remedies. Failure to obtain such a waiver, complete a refinancing or other restructuring, obtain an extension of the Springing Maturity Date as defined in the Credit Agreements or to reach an agreement with required lender groups under the Credit Agreements prior to May 16, 2020 or to reach an agreement with the Company's stakeholders on the terms of an out-of-court restructuring would have a material adverse effect on the Company's liquidity, financial condition and results of operations and may result in filing a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in order to implement a restructuring plan. The Company’s Consolidated Financial Statements as of March 31, 2020 are being prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited Consolidated Financial Statements, which have been prepared in accordance with the applicable rules of the Securities and Exchange Commission ("SEC"), include all adjustments (of a normal and recurring nature) that management considers necessary to fairly state the Company's results of operations, financial position and cash flows. The December 31, 2019 Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“U.S. GAAP”). These interim Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and Footnotes included in the Company’s audited financial statements in its Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on March 25, 2020 (the "2019 10-K"). Interim results are not necessarily indicative of the results that may be expected for the remainder of the year ending December 31, 2020. The preparation of the financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates on assumptions that it believes to be reasonable under the circumstances, including considerations for the impact from the outbreak of the COVID-19 pandemic on the Company's business due to various global macroeconomic, operational and supply chain risks as a result of COVID-19. Actual results could differ from the original estimates, requiring adjustments to these balances in future periods. Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-used software. This standard is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Accordingly, the Company has adopted this ASU in the first quarter of 2020, which did not have a material impact on its Consolidated Financial Statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments , which introduces a new model to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. This standard is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has adopted this ASU in the first quarter of 2020, which did not have a material impact on its Consolidated Financial Statements. The majority of the Company's domestic store and e-commerce revenues are received as cash at the point of sales. The majority of the Company's franchise and wholesale revenues are billed with varying terms for payment. An allowance for credit losses is established based on the aging of the accounts receivable balances, financial condition of our franchisees and other third-party customers, historical write-off experience and current and future economic and market conditions. The allowance for credit losses related to accounts receivable as of March 31, 2020 and changes for the three months then ended are as follows: (in thousands) Balance at December 31, 2019 Charged to costs and expenses Deduction Balance at March 31, 2020 Vendor allowance (1) $ 14,033 $ 5,439 $ (6,707) $ 12,765 Trade accounts receivable allowance (2) 8,615 9,224 (3,214) 14,625 (1) Changes to vendor allowance reserves are recorded as cost of sales on the Consolidated Statement of Operations. (2) Changes to trade accounts receivable allowance are recorded as selling, general and administrative on the Consolidated Statement of Operations The Company recognized a $8.7 million allowance for credit losses for its franchisees and other third-party customers and $4.6 million vendor allowance reserves during the three months ended March 31, 2020 based on the current and estimated adverse impacts from the COVID-19. Refer to Note 15. "Subsequent Events" for more information on the uncertainty that exists regarding the impacts of COVID-19. Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes , which simplifies accounting for income taxes by eliminating certain exceptions to ASC 740 related to the general approach for intraperiod tax allocation, methodology for calculating income taxes in an interim period and recognition of deferred taxes when there are investment ownership changes. The new guidance also simplifies aspects of accounting for franchise taxes and interim period effects of enacted changes in tax laws or rates. The new guidance provides clarification on accounting for transactions that result in a step-up in the tax basis of goodwill and allocation of consolidated income tax expense to separate financial statements of entities not subject to income tax. This ASU is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. The Company is evaluating the impact this standard will have on its Consolidated Financial Statements and related disclosures.

REVENUE

REVENUE	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE Revenue is recognized when obligations under the terms of a contract with the customer are satisfied. Generally, this occurs with the transfer of control of products or services. The Company satisfies performance obligations either over time or at a point in time as discussed in further detail below. Revenue is measured as the amount of consideration expected to be received in exchange for transferring goods or providing services. Applicable sales tax collected concurrent with revenue-producing activities is excluded from revenue. U.S. and Canada Revenue The following is a summary of revenue disaggregated by major source in the U.S. and Canada segment: Three months ended March 31, 2020 2019 U.S. company-owned product sales: (1) (in thousands) Protein $ 73,808 $ 80,257 Performance supplements 67,992 74,778 Weight management 20,516 30,779 Vitamins 48,962 47,056 Herbs / Greens 13,805 15,873 Wellness 39,082 47,200 Health / Beauty 39,485 46,388 Food / Drink 19,199 28,243 General merchandise 4,871 6,800 Total U.S. company-owned product sales $ 327,720 $ 377,374 Wholesale sales to franchisees 51,056 58,257 Royalties and franchise fees 7,327 8,472 Sublease income 10,242 10,976 Cooperative advertising and other franchise support fees 4,408 5,067 Other (2) 23,428 29,011 Total U.S. and Canada revenue $ 424,181 $ 489,157 (1) Includes e-commerce sales. (2) Includes revenue primarily related to operations in Canada and the loyalty programs, myGNC Rewards and PRO Access. International Revenues The following is a summary of revenue disaggregated by major source in the International reportable segment: Three months ended March 31, 2020 2019 (in thousands) Wholesale sales to franchisees $ 20,183 $ 25,437 Royalties and franchise fees 6,508 6,202 Other (1) 6,854 9,284 Total International revenue $ 33,545 $ 40,923 (1) Includes revenue related to China operations prior to the transfer of the China business to the HK JV and China JV, which was effective February 13, 2019, wholesale sales to the HK JV and China JV, and revenue from company-owned locations in Ireland. Manufacturing / Wholesale Revenue The following is a summary of revenue disaggregated by major source in the Manufacturing / Wholesale reportable segment: Three months ended March 31, 2020 2019 (in thousands) Third-party contract manufacturing (1) $ — $ 15,783 Intersegment sales (1) — 35,505 Wholesale partner sales 14,855 18,901 Total Manufacturing / Wholesale revenue $ 14,855 $ 70,189 (1) As a result of the transfer of the Nutra manufacturing business to the newly formed Manufacturing JV effective March 1, 2019, no third-party contract manufacturing and intersegment sales were recognized thereafter. Revenue by Geography The following is a summary of revenue by geography: Three months ended March 31, 2020 2019 Total revenues by geographic areas (1) : (in thousands) United States $ 452,873 $ 535,943 Foreign 19,708 28,821 Total revenues $ 472,581 $ 564,764 (1) Geographic areas are defined based on legal entity jurisdiction. Balances from Contracts with Customers Contract liabilities include payments received in advance of performance under the contract, and are realized with the associated revenue recognized under the contract. The Company's PRO Access and loyalty program points are recorded within deferred revenue and other current liabilities on the Consolidated Balance Sheets. Deferred franchise and license fees are recorded within deferred revenue and other current liabilities and other long-term liabilities on the Consolidated Balance Sheets. The following table presents changes in the Company’s contract liabilities: Three months ended March 31, 2020 Balance at Beginning of Period Recognition of revenue included in beginning balance Contract liability, net of revenue, recognized during the period Balance at the End of Period (in thousands) Deferred franchise and license fees $ 28,293 (2,722) 1,303 $ 26,874 PRO Access and loyalty program points (1) 22,896 (11,879) 11,096 22,113 Gift card liability (1) 3,110 (1,367) 207 1,950 Three months ended March 31, 2019 Balance at Beginning of Period Recognition of revenue included in beginning balance Contract liability, net of revenue, recognized during the period Balance at the End of Period (in thousands) Deferred franchise and license fees $ 33,464 (2,861) 668 $ 31,271 PRO Access and loyalty program points (1) 24,836 (12,423) 12,863 25,276 Gift card liability (1) 3,416 (1,523) 181 2,074 (1) Net of estimated breakage

INVENTORY

INVENTORY	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
INVENTORY	INVENTORY The net realizable value of inventory consisted of the following: March 31, 2020 December 31, 2019 (in thousands) Finished product ready for sale $ 367,402 $ 387,655 Inventory $ 367,402 $ 387,655

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	PROPERTY, PLANT AND EQUIPMENT, NET As previously disclosed, as a result of the COVID-19 pandemic, the Company has temporarily closed approximately 1,100, or 30%, of the U.S. and Canada company-owned and franchise stores as of March 31, 2020 and sales trends have significantly declined in the second half of March 2020. Some of the stores temporarily closed may be closed permanently in the future. Due to the store closures, decline in sales trends and estimated adverse impact from COVID-19, the Company recorded $40.3 million of impairment charges and other store closing costs, of which $21.2 million related to right-of-use asset impairments, $11.2 million related to property and equipment impairment and $7.9 million related to other store closing costs, presented as long-lived asset impairments and other store closing costs in the accompanying Consolidated Statement of Operations. Refer to Note 15. "Subsequent Events" for more information on the uncertainty that exists regarding the impacts of COVID-19. The impairment test was performed at the individual store level, as it is the lowest level in which identifiable cash flows are largely independent of other groups of assets and liabilities. If the undiscounted estimated cash flows were less than the carrying value of the asset group, an impairment charge was calculated by subtracting the estimated fair value of the asset group from its carrying value. Fair value for property, plant and equipment was estimated using a discounted cash flow method (income approach) utilizing the undiscounted cash flows computed in the first step of the test. Fair value for right-of-use asset was estimated using a discounted cash flow method (income approach) based on market participant assumptions. During the three months ended March 31, 2020, the Company sold its owned location in Boston, MA and recorded a $2.1 million pre-tax gain from the sale recognized within other income, net on the Company's Consolidated Statements of Operations.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Due to the significant decline in the Company's share price in the first quarter of 2020 and current circumstances and estimated adverse impacts from the COVID-19 pandemic, management concluded a triggering event occurred in the first quarter requiring an impairment test of its definite-lived intangible assets, indefinite-lived intangible brand name asset and the goodwill of all reporting units. Refer to Note 15. "Subsequent Events" for more information on the uncertainty that exists regarding the impacts of COVID-19. No impairment was recorded for the Company's definite-lived intangible assets. Brand Name Management performed an impairment test for its brand intangible asset, and concluded that the estimated fair value under the relief from royalty method (income approach) was less than its carrying value, which resulted in an impairment charge of $111.7 million. The brand name impairment test was performed in totality as it represents a single unit of account and $88.6 million of the charge was allocated to the U.S. and Canada and the remaining amount was allocated to the International segment. Key assumptions included in the estimation of the fair value include the following: • Future cash flow assumptions - Future cash flow assumptions include retail sales from the Company’s corporate retail store operations, GNC.com retail sales, wholesale partner sales, China JV and HK JV retail sales, and domestic and international franchise retail sales. Sales were based on organic growth and were derived from historical experience and assumptions regarding future growth, including considerations for the impact from the outbreak of the COVID-19 pandemic on the Company's business. The Company's analysis incorporated an assumed period of cash flows of 10 years with a terminal value. • Royalty rate - The royalty rates utilized consider external market evidence and internal financial metrics including a review of available returns after the consideration of property, plant and equipment, working capital and other intangible assets. The royalty rate used to estimate the fair values of the Company's reporting units was within a range of 0% - 3%. • Discount rate - The discount rate was based on an estimated weighted average cost of capital ("WACC") for each business supported by the GNC brand name. The components of WACC are the cost of equity and the cost of debt, each of which requires judgment by management to estimate. The Company developed its cost of equity estimate based on perceived risks and predictability of future cash flows. The WACC used to estimate the fair values of the Company's reporting units was within a range of 20% to 22%. Any difference between the WACC among reporting units is primarily due to the precision with which management expects to be able to predict the future cash flows of each reporting unit. Goodwill Management performed an impairment test of the Company's goodwill. The results of the impairment test indicated no impairments for GNC.com, International Franchise and Wholesale reporting units. However, The Health Store reporting unit had a fair value below its carrying value, which resulted in a $5.5 million goodwill impairment charge, which was recorded within the International segment. The Company estimated the fair values of its reporting units in the first quarter of 2020 using a discounted cash flow method (income approach) weighted 50% and a guideline company method (market approach) weighted 50%. The key assumptions used under the income approach include the following: • Future cash flow assumptions - The Company's projections for its reporting units were based on organic growth and were derived from historical experience and assumptions regarding future growth and profitability trends, including considerations for the impact from the outbreak of the COVID-19 pandemic on the Company's business. The Company's analysis incorporated an assumed period of cash flows of 10 years with a terminal value. • Discount rate - The discount rate was based on an estimated weighted average cost of capital ("WACC") for each reporting unit. The components of WACC are the cost of equity and the cost of debt, each of which requires judgment by management to estimate. The Company developed its cost of equity estimate based on perceived risks and predictability of future cash flows. The WACC used to estimate the fair values of the Company's reporting units was within a range of 20% to 22%. Any difference between the WACC among reporting units is primarily due to expectation of achieving the future cash flows of each reporting unit. The guideline company method involves analyzing transaction and financial data of publicly-traded companies to develop multiples, which are adjusted to account for differences in growth prospects and risk profiles of the reporting unit and comparable. Goodwill Roll-Forward The following table summarizes the Company's goodwill activity by reportable segment: U.S. and Canada International Manufacturing / Wholesale Total (in thousands) Goodwill at December 31, 2019 Gross $ 389,895 $ 43,330 $ 141,299 $ 574,524 Accumulated impairments (380,644) — (114,771) (495,415) Goodwill 9,251 43,330 26,528 79,109 2020 Activity: Impairment — (5,451) — (5,451) Translation effect of exchange rates — (106) — (106) Total 2020 activity — (5,557) — — (5,557) Balance at March 31, 2020 Gross 389,895 43,224 141,299 574,418 Accumulated impairments (380,644) (5,451) (114,771) (500,866) Goodwill $ 9,251 $ 37,773 $ 26,528 $ 73,552 Intangible Assets The following table reflects the gross carrying amount and accumulated amortization for each major definite-lived intangible assets: March 31, 2020 December 31, 2019 Weighted-Average Life Cost Accumulated Amortization/Impairment Carrying Amount Cost Accumulated Amortization/Impairment Carrying Amount (in thousands) Brand name Indefinite $ 720,000 $ (531,000) $ 189,000 $ 720,000 $ (419,280) $ 300,720 Retail agreements 30.3 31,000 (13,882) 17,118 31,000 (13,619) 17,381 Franchise agreements 25 70,000 (36,517) 33,483 70,000 (35,817) 34,183 Manufacturing agreements 25 40,000 (20,867) 19,133 40,000 (20,467) 19,533 Other intangibles 6.8 627 (541) 86 639 (529) 110 Franchise rights 3 $ 7,566 $ (7,495) $ 71 $ 7,566 $ (7,475) $ 91 Total $ 869,193 $ (610,302) $ 258,891 $ 869,205 $ (497,187) $ 372,018

DEBT _ INTEREST EXPENSE

DEBT / INTEREST EXPENSE	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
DEBT / INTEREST EXPENSE	DEBT / INTEREST EXPENSE Debt consisted of the following: March 31, December 31, (in thousands) Tranche B-2 Term Loan (net of $2.0 million and $7.0 million discount) 434,773 441,500 FILO Term Loan (net of $1.1 million and $8.2 million discount) 273,898 266,814 Notes (net of $2.4 million and $3.9 million conversion feature and $0.3 million and $0.5 million discount) 156,427 154,675 Revolving Credit Facility 30,000 — Debt issuance costs (76) (424) Total debt 895,022 862,565 Less: current debt (895,022) (180,566) Long-term debt $ — $ 681,999 On February 28, 2018, the Company amended and restated its Senior Credit Facility (the "Amendment", and the Senior Credit Facility as so amended, the "Term Loan Agreement"), which included an extension of the maturity date of the Tranche B-2 Term Loan. In the event that all outstanding amounts under the convertible senior notes exceeding $50 million are not repaid, refinanced, converted or effectively discharged prior to May 16, 2020, the Springing Maturity Date, the maturity date of the Tranche B-2 Term Loan will become the Springing Maturity Date, subject to certain adjustments. As of March 31, 2020, the Company had $434.8 million, net of discount, outstanding under the Tranche B-2 Term Loan. On February 28, 2018, the Company also entered into the ABL Credit Agreement, consisting of: • a $275.0 million asset-based Term Loan Facility advanced on a “first-in, last-out” basis (the "FILO Term Loan") with a maturity date of December 2022 (which maturity date will become May 2020, subject to certain adjustments, should the Springing Maturity Date be triggered); and • a $100 million asset-based Revolving Credit Facility (the "Revolving Credit Facility") with a maturity date of August 2022 (which maturity date will become May 2020, subject to certain adjustments, should the Springing Maturity Date be triggered). In connection with the transfer of the Nutra manufacturing and Anderson facility net assets to the manufacturing joint venture (the "Manufacturing JV") with International Vitamin Corporation ("IVC"), the Revolving Credit Facility commitment was reduced from $100 million to $81 million effective March 2019. As of March 31, 2020, there were $30.0 million borrowings outstanding on the Revolving Credit Facility. At March 31, 2020, the Company had $19.9 million available under the Revolving Credit Facility, after giving effect to $30.0 million borrowing outstanding, $4.5 million utilized to secure letters of credit and a $26.6 million reduction to borrowing ability as a result of decrease in net collateral. The Tranche B-2 Term Loan requires annual aggregate principal payments of at least $43 million and bears interest at a rate of, at the Company's option, LIBOR plus a margin of 8.75% per annum subject to change under certain circumstances (with a minimum and maximum margin of 8.25% and 9.25%, respectively, per annum), or prime plus a margin of 7.75% per annum subject to change under certain circumstances (with a minimum and maximum margin of 7.25% and 8.25%, respectively, per annum). Any mandatory repayments as defined in the credit agreement shall be applied to the remaining annual aggregate principal payments in direct order of maturity. The Company paid $100 million on the Tranche B-2 Term Loan in November 2018 and elected to use the payment to satisfy the scheduled amortization payments on the Term Loan Facility through December 2020. The Term Loan Agreement is secured by a (i) first lien on certain assets of the Company primarily consisting of capital stock issued by General Nutrition Centers, Inc. ("Centers") and its subsidiaries, intellectual property and equipment (“Term Priority Collateral”) and (ii) second lien on certain assets of the Company primarily consisting of inventory and accounts receivable (“ABL Priority Collateral”). The Term Loan Agreement is guaranteed by all material, wholly-owned domestic subsidiaries of the Company (the “U.S. Guarantors”) and by General Nutrition Centres Company, an unlimited liability company organized under the laws of Nova Scotia (together with the U.S. Guarantors, the “Guarantors”). There are no scheduled amortization payments associated with the FILO Term Loan, which bears interest at a rate of, at the Company's option, LIBOR plus a margin of 7.00% per annum subject to decrease under certain circumstances (with a minimum possible interest rate of LIBOR plus a margin of 6.50% per annum) or prime plus a margin of 6.00% per annum subject to decrease under certain circumstances (with a minimum possible interest rate of prime plus a margin of 5.50% per annum). Outstanding borrowings under the Revolving Credit Facility bear interest at a rate of LIBOR plus 1.50% per annum (subject to an increase of 0.25% or 0.50% based on the amount available to be drawn under the Revolving Credit Facility) or prime plus a margin of 0.50% per annum (subject to an increase of 0.25% or 0.50% based on the amount to be drawn under the Revolving Credit Facility). The Company is also required to pay an annual fee to revolving lenders equal to 1.5% per annum (subject to an increase of 0.25% or 0.50% based on the amount available to be drawn under the Revolving Credit Facility) on outstanding letters of credit and an annual commitment fee of 0.375% on the undrawn portion of the Revolving Credit Facility, which is subject to an increase to 0.5% based on the amount available to be drawn under the Revolving Credit Facility. The FILO Term Loan and Revolving Credit Facility are secured by a (i) first lien on ABL Priority Collateral and (ii) second lien on Term Priority Collateral. The FILO Term Loan and Revolving Credit Facility are guaranteed by the Guarantors. Under the Company’s Credit Agreements, the Company is required to make certain mandatory prepayments, including a requirement to prepay first the Tranche B-2 Term Loan (until repaid in full) and second the FILO Term Loan (until repaid in full, but only if such prepayment is permitted under the ABL Credit Agreement) in each case annually with amounts based on excess cash flow, as defined in the Company’s Credit Facilities, based on the results of the Company for the prior fiscal year. The payment will be 75% of excess cash flow for each such fiscal year, subject to a reduction to 50% based on the attainment of a certain Consolidated Net First Lien Leverage Ratio, and will be reduced by certain scheduled debt payment amounts. Based on the Company's results for the year ended December 31, 2019, the Company made an excess cash flow payment of $25.9 million in April 2020. The Company made an excess cash flow payment of $9.8 million in April 2019 with respect to the year ending December 31, 2018. At March 31, 2020, the Company's contractual interest rates under the Tranche B-2 Term Loan, the FILO Term Loan and the Revolving Credit Facility were 10.1%, 8.0% and 4.0%, respectively, which consist of LIBOR plus the applicable margin rate and in the case of Revolving Credit Facility at Prime rate plus the applicable margin rate. At December 31, 2019, the interest rates under the Tranche B-2 Term Loan and the FILO Term Loan were 10.6%, and 8.8%, respectively. The Company’s Credit Facilities contain customary covenants, including limitations on the ability of GNC Corporation, Centers, and Centers' subsidiaries to, among other things, incur debt, grant liens on their assets, enter into mergers or liquidations, sell assets, make investments or acquisitions, make optional payments in respect of, or modify, certain other debt instruments, pay dividends or other payments on capital stock, or enter into arrangements that restrict their ability to pay dividends or grant liens. Despite these limitations, the Company has the ability to discharge the liabilities of GNC Holdings, Inc. in the ordinary course of business through a variety of alternatives, including a restricted payment basket, a junior lien debt incurrence basket, and repayment of intercompany debt. In addition, the Term Loan Agreement requires compliance, as of the end of each fiscal quarter of the Company, with a maximum Consolidated Net First Lien Leverage Ratio currently set at 4.25 to 1.00. If the Company’s availability under the Revolving Credit Facility is less than the greater of (i) 12.5% of the borrowing base or (ii) $12.5 million, then the ABL Credit Agreement requires compliance as of the end of each fiscal quarter with a minimum Fixed Charge Coverage Ratio of 1.00 to 1.00. The Company is currently in compliance with the terms of its Credit Agreements. Given current circumstances around the COVID-19 pandemic as discussed further in Note 15, "Subsequent Events", there can be no assurances as our ability to remain in compliance with the financial covenants under the Senior Credit Facility Agreements over the next twelve months. As of March 31, 2020, the Company maintains $159.1 million in principal amount of its 1.5% convertible Notes. The Notes consist of the following components: March 31, 2020 December 31, 2019 (in thousands) Liability component Principal $ 159,097 $ 159,097 Conversion feature (2,356) (3,898) Discount related to debt issuance costs (314) (524) Net carrying amount $ 156,427 $ 154,675 As mentioned in Note 1, "Nature of Business," substantial doubt exists concerning the Company's ability to reduce the outstanding balance on the Notes to below $50.0 million. Given this, if we cannot reduce the outstanding balance under the Notes prior to May 16, 2020, the Springing Maturity Date, the Tranche B-2 Term Loan, the Revolving Credit Facility and the FILO Term Loan maturity will accelerate. While the Company continues to work through a number of refinancing alternatives to address its upcoming debt maturities, the Company cannot make any assurances regarding the likelihood, certainty or exact timing of any alternatives. As of March 31, 2020, all debt has been reclassified to current on the Consolidated Balance Sheets. In addition, the Company accelerated the amortization of original issuance discount and deferred financing fees for the Tranche B-2 Term Loan, FILO Term Loan and the Revolving Credit Facility of $12.4 million to the Springing Maturity Date. Interest Rate Swaps On June 13, 2018, the Company entered into two interest rate swaps with notional amounts of $275 million and $225 million to limit the exposure of its variable interest rate debt by effectively converting it to a fixed interest rate. The Company receives payments based on the one-month LIBOR and makes payments based on a fixed rate. The Company receives payments with a floor of 0.00% and 0.75%, respectively, on the $275 million and $225 million interest rate swaps, which aligns with the related debt instruments. The interest rate swap agreements had an effective date of June 29, 2018. The $225 million interest rate swap expires on February 28, 2021, and the $275 million interest rate swap expires on June 30, 2021. The notional amount of the $225 million interest rate swap has scheduled decreases to $175 million on June 30, 2019, $125 million on June 30, 2020 and $75 million on December 31, 2020. The Company designated these instruments as cash flow hedges deemed effective upon initiation. The interest rate swaps are recognized on the balance sheet at fair value. When the cash flow hedges are deemed effective, changes in fair value are recorded within other comprehensive loss on the Consolidated Balance Sheets and reclassified into the Consolidated Statement of Operations as interest expense in the period in which the underlying transaction affects earnings. The fair values of the derivative financial instruments included in the Consolidated Balance Sheets consisted of the following: Fair Value at Balance Sheet Classification March 31, 2020 December 31, 2019 (in thousand) Other current liabilities $ 9,080 $ 5,013 Other long-term liabilities 1,730 1,927 Total liabilities $ 10,810 $ 6,940 As mentioned above, if the Company cannot reduce the outstanding balance on the Notes to below $50 million before the Springing Maturity date, the maturity date of the Tranche B-2 and the FILO Term Loan will accelerate. Management does not expect to have sufficient cash flows from operations to repay the indebtedness before the Springing Maturity date. As such, the Company deemed the cash flow hedges as ineffective as the forecasted hedging transactions will not occur by the end of the originally specified time period. The Company reclassified a $10.8 million pre-tax loss previously deferred within accumulated other comprehensive loss to interest expense during the three months ended March 31, 2020. Interest Expense Interest expense consisted of the following: Three months ended March 31, 2020 2019 (in thousands) Tranche B-1 Term Loan coupon $ — $ 928 Tranche B-2 Term Loan coupon 12,339 16,468 FILO Term Loan coupon 6,826 6,751 Revolving Credit Facility 149 123 Amortization of discount and debt issuance costs 15,055 6,043 Subtotal 34,369 30,313 Notes: Coupon 596 707 Amortization of conversion feature 1,542 1,701 Amortization of discount and debt issuance costs 217 244 Total Notes 2,355 2,652 Loss on interest rate swap 10,810 — Other (90) (9) Interest expense, net $ 47,444 $ 32,956

EQUITY METHOD INVESTMENTS

EQUITY METHOD INVESTMENTS	3 Months Ended
	Mar. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
EQUITY METHOD INVESTMENTS	EQUITY METHOD INVESTMENTS The Company's interests in the Manufacturing, HK and China joint ventures are accounted for as equity method investments due to the Company’s ability to exercise significant influence over management decisions of the joint ventures. Under the equity method, the Company's share of profits and losses from the joint ventures is recorded within income from equity method investments on the Consolidated Statement of Operations. The following table provides a reconciliation of equity method investments on the Company’s Consolidated Balance Sheets: March 31, 2020 December 31, 2019 (in thousands) Manufacturing JV $ 56,684 $ 75,434 Manufacturing JV capital contribution 10,714 10,714 HK JV and China JV 10,200 10,342 Income from equity method investments 4,618 5,296 Distributions received from equity method investments (3,856) (3,856) Manufacturing JV other-than-temporary impairment (35,840) — Total Equity method investments $ 42,520 $ 97,930 In February 2019, the Company contributed its China business in exchange for 35% ownership of each of the formed joint ventures with Harbin, the HK JV and China JV. The HK JV includes the operation of the cross-border China e-commerce business, and has an exclusive right to use the Company’s trademarks to manufacture and distribute the Company’s products in China (excluding Hong Kong, Taiwan and Macau) via e-commerce channels. The China JV is a retail-focused joint venture to operate GNC's brick-and-mortar retail business in China and it will have an exclusive right to use the Company's trademarks to manufacture and distribute the Company's products in China (excluding Hong Kong, Taiwan and Macau) via retail stores and pharmacies. The HK JV closed in February 2019 and the China JV agreement is expected to be completed in the second quarter of 2020, following the satisfaction of certain routine regulatory and legal requirements. In March 2019, the Company entered into a strategic joint venture with IVC regarding the Company's manufacturing business. The Manufacturing JV is responsible for the manufacturing of the products previously produced by the Company at the Nutra manufacturing facility. The Company received $99.2 million from IVC and contributed the net assets of the Nutra manufacturing and Anderson facilities in exchange for an initial 43% equity interest in the Manufacturing JV. In addition, the Company made a capital contribution of $10.7 million to the Manufacturing JV to fund its share of short-term working capital needs. Under the terms of the agreement, IVC has the ability to pay an additional $75.0 million over a four Gain (loss) from the net asset exchange In connection with the formation of the joint ventures effective in the first quarter of 2019, the Company deconsolidated its China business and its Nutra manufacturing business which resulted in a pre-tax gain of $5.8 million and loss of $27.1 million, respectively, recorded within loss on net asset exchange for the formation of the joint ventures on the Consolidated Statements of Operations. The $5.8 million gain from the Harbin transaction was calculated based on the difference between the fair value of the 35% equity interest in the HK JV and China JV, less the carrying value of the contributed China business, including $2.4 million of cash, and third-party closing fees. The $27.1 million loss from the Manufacturing JV transaction was calculated based on the fair value of the 43% equity interest retained in the Manufacturing JV and the $101 million in cash received, less a $1.8 million working capital purchase price adjustment in the second quarter of 2019, less the carrying value of the contributed Nutra and Anderson facilities and third-party closing fees. As mentioned above, the Company received $15.6 million from IVC in connection with the subsequent purchase of the ownership of the Manufacturing JV in the first quarter of 2020, which resulted in a pre-tax loss of $3.1 million on net asset exchange calculated based on the difference between the cash receipt and the purchase price of $18.8 million. The loss was recorded in (loss) income from equity method investment within the Consolidated Statement of Operations. Additionally, in the first quarter of 2020, the Company recognized a $1.7 million purchase price adjustment related to the Harbin transaction, which was recorded as a loss on net asset exchange within the Consolidated Statements of Operations during the three months ended March 31, 2020. Other-Than-Temporary Impairment Due to the current and estimated adverse impacts from the COVID-19 pandemic and the Company's store closures, management expects a decrease in future purchases from the Manufacturing JV resulting in a decline in the value of its equity method investment in the Manufacturing JV. The decline in value was determined to be other-than-temporary which required the equity method investment to be written down to its fair value. The Company recognized $35.8 million other-than-temporary impairment related to its equity method investment in the Manufacturing JV, which was recorded within (loss) income from equity method investment on the Consolidated Statement of Operations during the three months ended March 31, 2020. This impairment charge was derived using Level 3 inputs and was primarily driven by the projected future purchase price of the equity interest in the Manufacturing JV from IVC under the terms of the agreement. As a result of the impairment, the carrying amount of the Company's equity method investment in the Manufacturing JV was $35.8 million less than its share of underlying equity in net assets as of March 31, 2020. Related Party transactions

FAIR VALUE MEASUREMENTS AND FIN

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS	FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS Accounting Standards Codification 820, Fair Value Measurements and Disclosures defines fair value as a market-based measurement that should be determined based on the assumptions that marketplace participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows: Level 1 — observable inputs such as quoted prices in active markets for identical assets and liabilities; Level 2 — observable inputs such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other inputs that are observable, or can be corroborated by observable market data; and Level 3 — unobservable inputs for which there are little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts of cash and cash equivalents, receivables, accounts payable, accrued liabilities and the Revolving Credit Facility approximate their respective fair values. Based on the interest rates currently available and their underlying risk, the carrying value of franchise notes receivable recorded in other long-term assets approximates its fair value. The carrying value and estimated fair value of the forward contracts for the issuance of convertible preferred stock, the Term Loan Facility, net of discount, Notes (net of the equity component classified in stockholders' equity and discount) and the interest rate swaps were as follows: March 31, 2020 December 31, 2019 Carrying Fair Carrying Fair (in thousands) Liabilities: Tranche B-2 Term Loan $ 434,773 $ 239,125 $ 441,500 $ 414,321 FILO Term Loan 273,898 231,786 266,814 265,851 Notes 156,427 148,606 154,675 148,488 Interest rate swaps 10,810 10,810 6,940 6,940 The fair values of the term loans were determined using the instruments' trading value in markets that are not active, which are considered Level 2 inputs. The fair value of the Notes was determined based on quoted market prices and bond terms and conditions, which are considered Level 2 inputs. The Company's interest rate swaps are carried at fair value, which is based primarily on Level 2 inputs utilizing readily observable market data, such as LIBOR forward rates, for all substantial terms of the interest rate swap contracts and the assessment of nonperformance risk. As described in Note 5, "Property, Plant and Equipment, Net," and Note 6, "Goodwill and Intangible Assets, Net," the Company recorded long-lived asset impairments during the three months ended March 31, 2020. This resulted in the following assets being measured at fair value on a non-recurring basis using Level 3 inputs: • the indefinite-lived brand name intangible asset at March 31, 2020; • goodwill at March 31, 2020 for the Health Store reporting unit; • property and equipment and right-of-use assets at certain of the Company's stores at March 31, 2020;

CONTINGENCIES

CONTINGENCIES	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	CONTINGENCIES The Company is engaged in various legal actions, claims and proceedings arising in the normal course of business, including claims related to breach of contracts, product liability matters, intellectual property matters and employment-related matters resulting from the Company's business activities. The Company's contingencies are subject to substantial uncertainties, including for each such contingency the following, among other factors: (i) the procedural status of the case; (ii) whether the case has or may be certified as a class action suit; (iii) the outcome of preliminary motions; (iv) the impact of discovery; (v) whether there are significant factual issues to be determined or resolved; (vi) whether the proceedings involve a large number of parties and/or parties and claims in multiple jurisdictions or jurisdictions in which the relevant laws are complex or unclear; (vii) the extent of potential damages, which are often unspecified or indeterminate; and (viii) the status of settlement discussions, if any, and the settlement posture of the parties. Consequently, except as otherwise noted below with regard to a particular matter, the Company cannot predict with any reasonable certainty the timing or outcome of the legal matters described below, and the Company is unable to estimate a possible loss or range of loss for such matters. If the Company ultimately is required to make any payments in connection with an adverse outcome in any of the matters discussed below, it is possible that it could have a material adverse effect on the Company's business, financial condition, results of operations or cash flows. As a manufacturer, prior to the formation of the Manufacturing JV, and retailer of nutritional supplements and other consumer products that are ingested by consumers or applied to their bodies, the Company has been and is currently subjected to various product liability claims. Although the effects of these claims to date have not been material to the Company, it is possible that current and future product liability claims could have a material adverse effect on its business or financial condition, results of operations or cash flows. The Company currently maintains product liability insurance with a deductible/retention of $4.0 million per claim with an aggregate cap on retained loss of $10.0 million per policy year. The Company typically seeks and has obtained contractual indemnification from most parties that supply raw materials for its products or that manufacture or market products it sells. The Company also typically seeks to be added, and has been added, as an additional insured under most of such parties' insurance policies. However, any such indemnification or insurance is limited by its terms and any such indemnification, as a practical matter, is limited to the creditworthiness of the indemnifying party and its insurer, and the absence of significant defenses by the insurers. Consequently, the Company may incur material product liability claims, which could increase its costs and adversely affect its reputation, revenue and operating income. Litigation DMAA / Aegeline Claims . Prior to December 2013, the Company sold products manufactured by third parties that contained derivatives from geranium known as 1.3-dimethylpentylamine/ dimethylamylamine/ 13-dimethylamylamine, or "DMAA," which were recalled from the Company's stores in November 2013, and/or Aegeline, a compound extracted from bael trees. As of March 31, 2020, the Company was named in 27 personal injury lawsuits involving products containing DMAA and/or Aegeline. These matters are currently stayed pending final resolution. The Company is contractually entitled to indemnification by its third-party vendors with regard to these matters, although the Company’s ability to obtain full recovery in respect of any such claims against it is dependent upon the creditworthiness of the vendors and/or their insurance coverage and the absence of any significant defenses available to their insurers. California Wage and Break Claims. On February 29, 2012, former Senior Store Manager, Elizabeth Naranjo, individually and on behalf of all others similarly situated, sued General Nutrition Corporation in the Superior Court of the State of California for the County of Alameda. The complaint contains eight causes of action, alleging, among other matters, meal, rest break and overtime violations for which indeterminate money damages for wages, penalties, interest, and legal fees are sought. In June 2018, the Court granted in part and denied in part the Company's Motion for Decertification. In August 2018, the plaintiff voluntarily dismissed the class action claims alleging overtime violations. In November 2019, GNC filed a renewed Motion for Decertification, which was denied by the Court in January 2020. Trial is currently scheduled for July 2020. As of March 31, 2020, an immaterial liability has been accrued in the accompanying financial statements. The Company intends to vigorously defend against the remaining class action claims asserted in this action. Pennsylvania Fluctuating Workweek . On September 18, 2013, Tawny Chevalier and Andrew Hiller commenced a class action in the Court of Common Pleas of Allegheny County, Pennsylvania. Plaintiff asserted a claim against the Company for a purported violation of the Pennsylvania Minimum Wage Act ("PMWA"), challenging the Company's utilization of the "fluctuating workweek" method to calculate overtime compensation, on behalf of all employees who worked for the Company in Pennsylvania and who were paid according to the fluctuating workweek method. In October 2014, the Court entered an order holding that the use of the fluctuating workweek method violated the PMWA. In September 2016, the Court entered judgment in favor of Plaintiffs and the class in an immaterial amount, which has been recorded as a charge in the accompanying Consolidated Financial Statements. Plaintiffs subsequently filed a petition for an award of attorney's fees, costs and incentive payment. The court awarded an immaterial amount in legal fees. The Company appealed the adverse judgment and the award of attorney's fees. On December 22, 2017, the Pennsylvania Superior Court held that the Company correctly determined the "regular rate" by dividing weekly compensation by all hours worked (rather than 40), but held that the regular rate must be multiplied by 1.5 (rather than 0.5) to determine the amount of overtime owed. Taking accumulated interest into account, the net result of the Superior Court's decision was to reduce the Company's liability by an immaterial amount, which has been reflected in the accompanying Consolidated Financial Statements. The Company filed a petition for appeal to the Pennsylvania Supreme Court on January 22, 2018. The Pennsylvania Supreme Court accepted the Company's petition for appeal and the Company filed its appellant’s brief on August 27, 2018. The Pennsylvania Supreme Court ruled in favor of Plaintiffs. The case has been remanded to the trial court for final resolution. Oregon Attorney General. On October 22, 2015, the Attorney General for the State of Oregon sued the Company in Multnomah County Circuit Court for alleged violations of Oregon’s Unlawful Trade Practices Act, in connection with its sale in Oregon of certain third-party products. The Company is vigorously defending itself against these allegations. Along with its Amended Answer and Affirmative Defenses, the Company filed a counterclaim for declaratory relief, asking the court to make certain rulings in favor of the Company, and adding USPlabs, LLC and SK Laboratories as counterclaim defendants. In March 2018, the Oregon Attorney General filed a motion for summary judgment relating to its first claim for relief, which the Company contested. The Company filed a cross motion for summary judgment on the first claim for relief, which the Oregon Attorney General contested. Following oral argument in August 2018, the Court denied the State’s motion for summary judgment and granted in part and denied in part the Company’s motion for summary judgment. The parties are in the process of exchanging discovery. Trial is currently scheduled to begin in September 2020. As any losses that may arise from this matter are not probable or reasonably estimable at this time, no liability has been accrued in the accompanying Consolidated Financial Statements. Moreover, the Company does not anticipate that any such losses are likely to have a material impact on the Company, its business or results of operations. The Company is contractually entitled to indemnification and defense by its third-party vendors. Ultimately, however, the Company's ability to obtain full recovery in respect of any such claims against it is dependent upon the creditworthiness of its vendors and/or their insurance coverage and the absence of any significant defenses available to their insurers. E-Commerce Pricing Matters . In April 2016, Jenna Kaskorkis, et al. filed a complaint against General Nutrition Centers, Inc. followed by similar cases brought forth by Ashley Gennock in May 2016 and Kenneth Harrison in December 2016. Plaintiffs allege that the Company's promotional pricing on its website was misleading and did not fairly represent promotions based on average retail prices over a trended period of time being consistent with prices advertised as promotional. A tentative agreement was reached in the third quarter of 2017 on many of the key terms of a settlement. In December 2019, the Court approved the settlement agreement. The Company currently expects any settlement to be in a form that does not require the recording of a contingent liability. Government Regulation In November 2013, the Company received a subpoena from the U.S. Department of Justice ("DOJ") for information related to its investigation of a third party product vendor, USPlabs, LLC. The Company fully cooperated with the investigation of the vendor and the related products, all of which were discontinued in 2013. In December 2016, the Company reached agreement with the DOJ in connection with the Company's cooperation, which agreement acknowledges the Company relied on the representations and written guarantees of USPlabs and the Company's representation that it did not knowingly sell products not in compliance with the Federal Food, Drug and Cosmetic Act (the "FDCA"). Under the agreement, which included an immaterial payment to the federal government, the Company will take a number of actions to broaden industry-wide knowledge of prohibited ingredients and improve compliance by vendors of third party products. These actions are in keeping with the leadership role the Company has taken in setting industry quality and compliance standards, and the Company's commitment over the course of the agreement (60 months) to support a combination of its own and the industry's initiatives. Some of these actions include maintaining and continuously updating a list of restricted ingredients that will be prohibited from inclusion in any products that are sold by the Company. Vendors selling products to the Company for the sale of such products by the Company will be required to warrant that the products sold do not contain any of these restricted ingredients. In addition, the Company will develop and maintain a list of ingredients that the Company believes comply with the applicable provisions of the FDCA. Environmental Compliance As part of soil and groundwater remediation conducted at the Nutra manufacturing facility pursuant to an investigation conducted in partnership with the South Carolina Department of Health and Environmental Control (the "DHEC"), the Company completed additional investigations with the DHEC's approval, including the installation and operation of a pilot vapor extraction system under a portion of the facility in the second half of 2016, which was an immaterial cost to the Company. After an initial monitoring period, in October of 2017 the DHEC approved a work plan for extended monitoring of such system and the contamination into 2021. While the Company contributed the net assets of the Nutra manufacturing and Anderson facilities to the Manufacturing JV in March of 2019 (refer to Note 8 “Equity Method Investments” for additional information), we retained certain liabilities, including historical environmental liabilities, related to the facilities. As such, the Company and the Manufacturing JV will continue to consult with the DHEC on the next steps in the work after their review of the results of the extended monitoring is complete. At this stage of the investigation, however, it is not possible to estimate the timing and extent of any additional remedial action that may be required, the ultimate cost of remediation, or the amount of our potential liability. Therefore, no liability has been recorded in the Company's Consolidated Financial Statements. In addition to the foregoing, the Company is subject to numerous federal, state, local and foreign environmental and health and safety laws and regulations governing its operations, including the handling, transportation and disposal of non-hazardous and hazardous substances and wastes, as well as emissions and discharges from its operations into the environment, including discharges to air, surface water and groundwater. Failure to comply with such laws and regulations could result in costs for remedial actions, penalties or the imposition of other liabilities, including certain historic liabilities retained by the Company pursuant to the terms of the Manufacturing JV. New laws, changes in existing laws or the interpretation thereof, or the development of new facts or changes in their processes could also cause the Company to incur additional capital and operating expenditures to maintain compliance with environmental laws and regulations and environmental permits. The Company is also subject to laws and regulations that impose liability and cleanup responsibility for releases of hazardous substances into the environment without regard to fault or knowledge about the condition or action causing the liability. Under certain of these laws and regulations, such liabilities can be imposed for cleanup of previously owned or operated properties, or for properties to which substances or wastes that were sent in connection with current or former operations at its facilities. From time to time, the Company has incurred costs and obligations for correcting environmental and health and safety noncompliance matters and for remediation at or relating to certain of the Company's current or former properties or properties at which the Company's waste has been disposed. However, compliance with the provisions of national, state and local environmental laws and regulations has not had a material effect upon the Company's capital expenditures, earnings, financial position, liquidity or competitive position. The Company believes it has complied with, and is currently complying with, its environmental obligations pursuant to environmental and health and safety laws and regulations and that any liabilities for noncompliance will not have a material adverse effect on its business, financial performance or cash flows. However, it is difficult to predict future liabilities and obligations, which could be material.

MEZZANINE EQUITY

MEZZANINE EQUITY	3 Months Ended
	Mar. 31, 2020
Temporary Equity Disclosure [Abstract]
MEZZANINE EQUITY	MEZZANINE EQUITY Holdings is authorized to issue up to 60.0 million shares of preferred stock, par value $0.001 per share. On February 13, 2018, the Company entered into a Securities Purchase Agreement (as amended from time to time, the “Securities Purchase Agreement”) by and between the Company and Harbin Pharmaceutical Group Holdings Co., Ltd. (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor, and the Investor agreed to purchase from the Company, 299,950 shares of a newly created series of convertible preferred stock of the Company, designated the “Series A Convertible Preferred Stock” (the “Convertible Preferred Stock”), for a purchase price of $1,000 per share, or an aggregate of approximately $300 million (the “Securities Purchase”). The Convertible Preferred Stock is convertible into 56.1 million shares of the Company's Common Stock at an initial conversion price of $5.35 per share, subject to customary anti-dilution adjustments. On November 7, 2018, The Company entered into an Amendment to the Securities Purchase Agreement with the Investor. Pursuant to the terms of the Securities Purchase Agreement, the Investor assigned its interest in the Securities Purchase Agreement to Harbin and funded the $300 million investment in three separate tranches. The shares of Convertible Preferred Stock were issued as follows: (i) 100,000 shares of Convertible Preferred Stock issued on November 8, 2018 for a total purchase price of $100 million (the "Initial Issuance"), (ii) 50,000 shares of Convertible Preferred Stock issued on January 2, 2019 for a total purchase price of $50 million (the "Second Issuance") and (iii) 149,950 shares of Convertible Preferred Stock issued on February 13, 2019 for a total purchase price of approximately $150 million (the “Third Issuance”). Holders of shares of Convertible Preferred Stock are entitled to receive cumulative preferential dividends, payable quarterly in arrears, at an annual rate of 6.5% of the stated value of $1,000 per share, subject to increase in connection with the payment of dividends in kind. Dividends are payable, at the Company's option, in cash from legally available funds or in kind by issuing additional shares of Convertible Preferred Stock with such stated value equal to the amount of payment being made or by increasing the stated value of the outstanding Convertible Preferred Stock by the amount per share of the dividend or in a combination thereof. As of March 31, 2020, the Company had issued a total of 299,950 shares of Convertible Preferred Stock. The Convertible Preferred Stock was recorded as Mezzanine Equity, net of issuance cost, on the Consolidated Balance Sheets because the shares are redeemable at the option of the holder if a fundamental change occurs, which includes change in control or delisting (a "Fundamental Change"). The guaranteed Second Issuance and Third Issuance were considered forward contracts that represented an obligation to both parties until the shares were issued. The forward contracts were recorded at fair value on the Consolidated Balance Sheets as of December 31, 2018, with any changes in fair value recorded in earnings in the Consolidated Statements of Operations. The Company recorded a $16.8 million loss on forward contracts for the issuance of Convertible Preferred Stock during the first quarter of 2019. Upon issuance of the shares associated with the forward contracts, the carrying value of the forward contracts were recorded to Mezzanine Equity.

EARNINGS PER SHARE

EARNINGS PER SHARE	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE The following table represents the Company's basic and dilutive weighted-average shares: Three months ended March 31, 2020 2019 (in thousands) Basic weighted average shares 83,897 83,510 Effect of dilutive stock-based compensation awards — — Diluted weighted average shares 83,897 83,510 For the three months ended March 31, 2020 and 2019, all 6.8 million and 4.0 million, respectively, outstanding stock-based awards were excluded from the computation of diluted earnings per shares ("EPS") because the Company was in a net loss position and as a result, inclusion of the awards would have been anti-dilutive. The Company has applied the if-converted method to calculate dilution on the Convertible Preferred Stock and the Notes in the current quarter, which has resulted in all 59.9 million and 2.4 million shares underlying the Convertible Preferred Stock and the Notes, respectively, being anti-dilutive. The computations for basic and diluted loss per common share are as follows: Three months ended March 31, 2020 2019 (in thousands, except per share data) Loss per common share - Basic Net loss $ (200,086) $ (15,262) Cumulative undeclared convertible preferred stock dividend 5,195 3,716 Net loss attributable to common shareholders (205,281) (18,978) Weighted average common shares outstanding - basic 83,897 83,510 Loss per common share - basic $ (2.45) $ (0.23) Loss per common share - Diluted Net loss $ (200,086) $ (15,262) Cumulative undeclared convertible preferred stock dividends 5,195 3,716 Net loss attributable to common shareholders (205,281) (18,978) Weighted average common shares outstanding - diluted 83,897 83,510 Loss per common share - diluted $ (2.45) $ (0.23)

SEGMENTS

SEGMENTS	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
SEGMENTS	SEGMENTS The Company aggregates its operating segments into three reportable segments, which include U.S. and Canada, International and Manufacturing / Wholesale. Warehousing and distribution costs have been allocated to each reportable segment based on estimated utilization and benefit. The Company's chief operating decision maker (its chief executive officer) evaluates segment operating results based primarily on operating income. Operating income of each reportable segment excludes certain items that are managed at the consolidated level, such as corporate costs. The Manufacturing / Wholesale segment, prior to the formation of the Manufacturing JV, manufactured and sold product to the U.S. and Canada and International segments at cost with a markup, which was eliminated at consolidation. Due to the current and estimated adverse impacts from the COVID-19 pandemic, during the three months ended March 31, 2020, the Company recorded $157.5 million long-lived asset impairments and other store closing costs ($128.9 million within U.S. and Canada; $28.6 million within International), $22.8 million reserves related to inventory obsolescence and vendor allowances ($22.4 million within U.S. and Canada; $0.4 million within Manufacturing / Wholesale), and $8.7 million allowance for doubtful accounts ($7.9 million within U.S. and Canada; $0.8 million within International). Refer to Note 15. "Subsequent Events" for more information on the uncertainty that exists regarding the impacts of COVID-19. The following table represents key financial information for each of the Company's reportable segments: Three months ended March 31, 2020 2019 (in thousands) Revenue: U.S. and Canada $ 424,181 $ 489,157 International 33,545 40,923 Manufacturing / Wholesale: Intersegment revenues — 35,505 Third-party contract manufacturing — 15,783 Wholesale partner sales 14,855 18,901 Subtotal Manufacturing / Wholesale 14,855 70,189 Total reportable segment revenues 472,581 600,269 Elimination of intersegment revenues — (35,505) Total revenue $ 472,581 $ 564,764 Operating income: U.S. and Canada $ (131,200) $ 52,100 International (17,382) 14,050 Manufacturing / Wholesale 6,931 15,344 Total reportable segment operating income (141,651) 81,494 Corporate costs (24,835) (26,261) Loss on net asset exchange for the formation of the joint ventures (1,655) (19,514) Other 2,107 (237) Unallocated corporate costs, loss on net asset exchange and other (24,383) (46,012) Total operating (loss) income (166,034) 35,482 Interest expense, net 47,444 32,956 Loss on forward contracts for the issuance of convertible preferred stock — 16,787 Loss before income taxes $ (213,478) $ (14,261) Refer to Note 3, "Revenue" for more information on the Company's reportable segments.

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Coronavirus Aid, Relief, and Economic Security Act ("CARES" Act) signed into law on March 27, 2020 in response to the COVID-19 pandemic, provides additional avenues of financial relief and assistance to individuals and businesses, including tax relief. The CARES Act includes, among other items, provisions relating to payroll tax credits and deferrals, net operating loss carry back periods, alternative minimum tax credits, and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also temporarily and retroactively increases the limitation on the deductibility of interest expense under Internal Revenue Code Section 163(j)(1) from 30% to 50% of adjusted taxable income for tax years beginning in 2019 and 2020. The Company is currently evaluating the impact of the provisions of the CARES Act. The Company recognized $53.0 million of income tax benefit during the three months ended March 31, 2020 compared with $2.0 million of income tax expense in the prior year quarter. The Company's income tax expense is based on income, statutory tax rates and tax planning opportunities available in the jurisdictions in which it operates. The Company’s year-to-date tax provision is calculated by applying the most recent annualized effective tax rate to year-to-date pre-tax ordinary income. The Company’s 2020 annual effective tax rate was impacted by a $27.6 million partial valuation allowance for attributes expected to be generated in 2020 that may not be realizable, the other-than-temporary impairment of the Manufacturing JV, and the benefit of the federal tax rate differential related to federal net operating losses generated during the current year that are expected to be carried back to prior years at a 35% rate. The 2019 effective tax rate was significantly impacted by a gain for tax purposes resulting from the transfer of the Nutra manufacturing net assets to the Manufacturing JV and the establishment of a partial valuation allowance for attributes generated in the 2019 year that may not be realizable. The tax impacts of unusual or infrequent items are recorded discretely in the interim period in which they occur. During the three months ended March 31, 2020, the Company discretely recorded a permanent $4.8 million benefit related to the release of valuation allowances on the Federal interest expense limitation generated in 2019, resulting from the passage of the CARES Act which retroactively changed the 2019 Federal interest expense limitation from 30% to 50% of adjusted taxable income. During the fourth quarter of the year ended December 31, 2019, as further discussed in Note 1, "Nature of Business," management concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern. Management considered this in concluding that certain deferred tax assets were no longer more likely than not realizable. As a result, increase in valuation allowance of $27.6 million and $27.1 million on the Company’s deferred tax assets were recorded as of March 31, 2020 and December 31, 2019, respectively, which related principally to Federal deferred tax assets, state NOL carryforwards, and other state tax attributes. These increases were partially offset by valuation allowance decreases of $4.8 million as of March 31, 2020 and December 31, 2019. At March 31, 2020 and December 31, 2019, the Company had $10.8 million and $10.7 million of unrecognized tax benefits, respectively, excluding interest and penalties, which if recognized, would affect the effective tax rate. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense. The Company accrued $2.8 million at March 31, 2020 and $2.1 million at December 31, 2019, for potential interest and penalties associated with uncertain tax positions. To the extent interest and penalties are not assessed with respect to the ultimate settlement of uncertain tax positions, amounts previously accrued will be reversed as a reduction to income tax expense. Holdings files a consolidated federal tax return and various consolidated and separate tax returns as prescribed by the tax laws of the state, local and international jurisdictions in which it and its subsidiaries operate. The statutes of limitation for the Company’s U.S. federal income tax returns are closed for years through 2013. The Company has various state and local jurisdiction tax years open to examination (the earliest open period is generally 2011).

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTSThe Company is closely monitoring the current and future potential impact of the COVID-19 pandemic on all aspects of our business and geographies, including how it will impact our customers, employees, suppliers, vendors, business partners and distribution channels. The Company incurred significant disruptions during the three months ended March 31, 2020 from COVID-19, and the Company's estimates on the future impact that COVID-19 will have on the Company's financial position and operating results is subject to numerous uncertainties. These uncertainties include the severity of the virus, the duration of the outbreak, governmental, business or other actions (which could include limitations on our operations), impacts on the Company's supply chain, the effect on customer demand, store closures or changes to our operations. The health of the Company's workforce, and the ability to meet staffing needs in stores, distribution facilities, wholesale operations and other critical functions cannot be predicted and is vital to our operations. Further, the impacts of a potential worsening of global economic conditions and the continued disruptions to, and volatility in, the credit and financial markets, consumer spending as well as other unanticipated consequences remain unknown. As of May 6, 2020, approximately 1,300, or 40%, of the U.S. and Canada company-owned and franchise retail stores were closed due to the COVID-19 pandemic. In addition, the Company cannot predict with certainty the impact that COVID-19 will have on its customers, vendors, suppliers and other business partners; however, any material effect on these parties could adversely impact the Company. The situation surrounding COVID-19 remains fluid, and the Company is actively managing its response in collaboration with customers, government officials, team members and business partners and assessing potential impacts to its financial position and operating results, as well as adverse developments in the business.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	BASIS OF PRESENTATION The accompanying unaudited Consolidated Financial Statements, which have been prepared in accordance with the applicable rules of the Securities and Exchange Commission ("SEC"), include all adjustments (of a normal and recurring nature) that management considers necessary to fairly state the Company's results of operations, financial position and cash flows. The December 31, 2019 Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“U.S. GAAP”). These interim Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and Footnotes included in the Company’s audited financial statements in its Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on March 25, 2020 (the "2019 10-K"). Interim results are not necessarily indicative of the results that may be expected for the remainder of the year ending December 31, 2020. The preparation of the financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates on assumptions that it believes to be reasonable under the circumstances, including considerations for the impact from the outbreak of the COVID-19 pandemic on the Company's business due to various global macroeconomic, operational and supply chain risks as a result of COVID-19. Actual results could differ from the original estimates, requiring adjustments to these balances in future periods.
Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-used software. This standard is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Accordingly, the Company has adopted this ASU in the first quarter of 2020, which did not have a material impact on its Consolidated Financial Statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments , which introduces a new model to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. This standard is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has adopted this ASU in the first quarter of 2020, which did not have a material impact on its Consolidated Financial Statements. The majority of the Company's domestic store and e-commerce revenues are received as cash at the point of sales. The majority of the Company's franchise and wholesale revenues are billed with varying terms for payment. An allowance for credit losses is established based on the aging of the accounts receivable balances, financial condition of our franchisees and other third-party customers, historical write-off experience and current and future economic and market conditions. The allowance for credit losses related to accounts receivable as of March 31, 2020 and changes for the three months then ended are as follows: (in thousands) Balance at December 31, 2019 Charged to costs and expenses Deduction Balance at March 31, 2020 Vendor allowance (1) $ 14,033 $ 5,439 $ (6,707) $ 12,765 Trade accounts receivable allowance (2) 8,615 9,224 (3,214) 14,625 (1) Changes to vendor allowance reserves are recorded as cost of sales on the Consolidated Statement of Operations. (2) Changes to trade accounts receivable allowance are recorded as selling, general and administrative on the Consolidated Statement of Operations The Company recognized a $8.7 million allowance for credit losses for its franchisees and other third-party customers and $4.6 million vendor allowance reserves during the three months ended March 31, 2020 based on the current and estimated adverse impacts from the COVID-19. Refer to Note 15. "Subsequent Events" for more information on the uncertainty that exists regarding the impacts of COVID-19. Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes , which simplifies accounting for income taxes by eliminating certain exceptions to ASC 740 related to the general approach for intraperiod tax allocation, methodology for calculating income taxes in an interim period and recognition of deferred taxes when there are investment ownership changes. The new guidance also simplifies aspects of accounting for franchise taxes and interim period effects of enacted changes in tax laws or rates. The new guidance provides clarification on accounting for transactions that result in a step-up in the tax basis of goodwill and allocation of consolidated income tax expense to separate financial statements of entities not subject to income tax. This ASU is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. The Company is evaluating the impact this standard will have on its Consolidated Financial Statements and related disclosures.

BASIS OF PRESENTATION (Tables)

BASIS OF PRESENTATION (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Accounts Receivable, Allowance for Credit Loss	The allowance for credit losses related to accounts receivable as of March 31, 2020 and changes for the three months then ended are as follows: (in thousands) Balance at December 31, 2019 Charged to costs and expenses Deduction Balance at March 31, 2020 Vendor allowance (1) $ 14,033 $ 5,439 $ (6,707) $ 12,765 Trade accounts receivable allowance (2) 8,615 9,224 (3,214) 14,625 (1) Changes to vendor allowance reserves are recorded as cost of sales on the Consolidated Statement of Operations. (2) Changes to trade accounts receivable allowance are recorded as selling, general and administrative on the Consolidated Statement of Operations

REVENUE (Tables)

REVENUE (Tables)	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	U.S. and Canada Revenue The following is a summary of revenue disaggregated by major source in the U.S. and Canada segment: Three months ended March 31, 2020 2019 U.S. company-owned product sales: (1) (in thousands) Protein $ 73,808 $ 80,257 Performance supplements 67,992 74,778 Weight management 20,516 30,779 Vitamins 48,962 47,056 Herbs / Greens 13,805 15,873 Wellness 39,082 47,200 Health / Beauty 39,485 46,388 Food / Drink 19,199 28,243 General merchandise 4,871 6,800 Total U.S. company-owned product sales $ 327,720 $ 377,374 Wholesale sales to franchisees 51,056 58,257 Royalties and franchise fees 7,327 8,472 Sublease income 10,242 10,976 Cooperative advertising and other franchise support fees 4,408 5,067 Other (2) 23,428 29,011 Total U.S. and Canada revenue $ 424,181 $ 489,157 (1) Includes e-commerce sales. (2) Includes revenue primarily related to operations in Canada and the loyalty programs, myGNC Rewards and PRO Access. International Revenues The following is a summary of revenue disaggregated by major source in the International reportable segment: Three months ended March 31, 2020 2019 (in thousands) Wholesale sales to franchisees $ 20,183 $ 25,437 Royalties and franchise fees 6,508 6,202 Other (1) 6,854 9,284 Total International revenue $ 33,545 $ 40,923 (1) Includes revenue related to China operations prior to the transfer of the China business to the HK JV and China JV, which was effective February 13, 2019, wholesale sales to the HK JV and China JV, and revenue from company-owned locations in Ireland. Manufacturing / Wholesale Revenue The following is a summary of revenue disaggregated by major source in the Manufacturing / Wholesale reportable segment: Three months ended March 31, 2020 2019 (in thousands) Third-party contract manufacturing (1) $ — $ 15,783 Intersegment sales (1) — 35,505 Wholesale partner sales 14,855 18,901 Total Manufacturing / Wholesale revenue $ 14,855 $ 70,189 (1) As a result of the transfer of the Nutra manufacturing business to the newly formed Manufacturing JV effective March 1, 2019, no third-party contract manufacturing and intersegment sales were recognized thereafter. Revenue by Geography The following is a summary of revenue by geography: Three months ended March 31, 2020 2019 Total revenues by geographic areas (1) : (in thousands) United States $ 452,873 $ 535,943 Foreign 19,708 28,821 Total revenues $ 472,581 $ 564,764
Contract with Customer	The following table presents changes in the Company’s contract liabilities: Three months ended March 31, 2020 Balance at Beginning of Period Recognition of revenue included in beginning balance Contract liability, net of revenue, recognized during the period Balance at the End of Period (in thousands) Deferred franchise and license fees $ 28,293 (2,722) 1,303 $ 26,874 PRO Access and loyalty program points (1) 22,896 (11,879) 11,096 22,113 Gift card liability (1) 3,110 (1,367) 207 1,950 Three months ended March 31, 2019 Balance at Beginning of Period Recognition of revenue included in beginning balance Contract liability, net of revenue, recognized during the period Balance at the End of Period (in thousands) Deferred franchise and license fees $ 33,464 (2,861) 668 $ 31,271 PRO Access and loyalty program points (1) 24,836 (12,423) 12,863 25,276 Gift card liability (1) 3,416 (1,523) 181 2,074 (1) Net of estimated breakage

INVENTORY (Tables)

INVENTORY (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Net Realizable Value of Inventory	The net realizable value of inventory consisted of the following: March 31, 2020 December 31, 2019 (in thousands) Finished product ready for sale $ 367,402 $ 387,655 Inventory $ 367,402 $ 387,655

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table summarizes the Company's goodwill activity by reportable segment: U.S. and Canada International Manufacturing / Wholesale Total (in thousands) Goodwill at December 31, 2019 Gross $ 389,895 $ 43,330 $ 141,299 $ 574,524 Accumulated impairments (380,644) — (114,771) (495,415) Goodwill 9,251 43,330 26,528 79,109 2020 Activity: Impairment — (5,451) — (5,451) Translation effect of exchange rates — (106) — (106) Total 2020 activity — (5,557) — — (5,557) Balance at March 31, 2020 Gross 389,895 43,224 141,299 574,418 Accumulated impairments (380,644) (5,451) (114,771) (500,866) Goodwill $ 9,251 $ 37,773 $ 26,528 $ 73,552
Schedule of Definite-Lived Intangible Assets	The following table reflects the gross carrying amount and accumulated amortization for each major definite-lived intangible assets: March 31, 2020 December 31, 2019 Weighted-Average Life Cost Accumulated Amortization/Impairment Carrying Amount Cost Accumulated Amortization/Impairment Carrying Amount (in thousands) Brand name Indefinite $ 720,000 $ (531,000) $ 189,000 $ 720,000 $ (419,280) $ 300,720 Retail agreements 30.3 31,000 (13,882) 17,118 31,000 (13,619) 17,381 Franchise agreements 25 70,000 (36,517) 33,483 70,000 (35,817) 34,183 Manufacturing agreements 25 40,000 (20,867) 19,133 40,000 (20,467) 19,533 Other intangibles 6.8 627 (541) 86 639 (529) 110 Franchise rights 3 $ 7,566 $ (7,495) $ 71 $ 7,566 $ (7,475) $ 91 Total $ 869,193 $ (610,302) $ 258,891 $ 869,205 $ (497,187) $ 372,018

DEBT _ INTEREST EXPENSE (Tables

DEBT / INTEREST EXPENSE (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Debt consisted of the following: March 31, December 31, (in thousands) Tranche B-2 Term Loan (net of $2.0 million and $7.0 million discount) 434,773 441,500 FILO Term Loan (net of $1.1 million and $8.2 million discount) 273,898 266,814 Notes (net of $2.4 million and $3.9 million conversion feature and $0.3 million and $0.5 million discount) 156,427 154,675 Revolving Credit Facility 30,000 — Debt issuance costs (76) (424) Total debt 895,022 862,565 Less: current debt (895,022) (180,566) Long-term debt $ — $ 681,999
Components of Convertible Debt	As of March 31, 2020, the Company maintains $159.1 million in principal amount of its 1.5% convertible Notes. The Notes consist of the following components: March 31, 2020 December 31, 2019 (in thousands) Liability component Principal $ 159,097 $ 159,097 Conversion feature (2,356) (3,898) Discount related to debt issuance costs (314) (524) Net carrying amount $ 156,427 $ 154,675
Schedule of Derivative Financial Instruments	The fair values of the derivative financial instruments included in the Consolidated Balance Sheets consisted of the following: Fair Value at Balance Sheet Classification March 31, 2020 December 31, 2019 (in thousand) Other current liabilities $ 9,080 $ 5,013 Other long-term liabilities 1,730 1,927 Total liabilities $ 10,810 $ 6,940
Schedule of Interest Expense	Interest expense consisted of the following: Three months ended March 31, 2020 2019 (in thousands) Tranche B-1 Term Loan coupon $ — $ 928 Tranche B-2 Term Loan coupon 12,339 16,468 FILO Term Loan coupon 6,826 6,751 Revolving Credit Facility 149 123 Amortization of discount and debt issuance costs 15,055 6,043 Subtotal 34,369 30,313 Notes: Coupon 596 707 Amortization of conversion feature 1,542 1,701 Amortization of discount and debt issuance costs 217 244 Total Notes 2,355 2,652 Loss on interest rate swap 10,810 — Other (90) (9) Interest expense, net $ 47,444 $ 32,956

EQUITY METHOD INVESTMENTS (Tabl

EQUITY METHOD INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Summary of Equity Method Investments	The following table provides a reconciliation of equity method investments on the Company’s Consolidated Balance Sheets: March 31, 2020 December 31, 2019 (in thousands) Manufacturing JV $ 56,684 $ 75,434 Manufacturing JV capital contribution 10,714 10,714 HK JV and China JV 10,200 10,342 Income from equity method investments 4,618 5,296 Distributions received from equity method investments (3,856) (3,856) Manufacturing JV other-than-temporary impairment (35,840) — Total Equity method investments $ 42,520 $ 97,930

FAIR VALUE MEASUREMENTS AND F_2

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Actual and Estimated Fair Values of the Financial Instruments	The carrying value and estimated fair value of the forward contracts for the issuance of convertible preferred stock, the Term Loan Facility, net of discount, Notes (net of the equity component classified in stockholders' equity and discount) and the interest rate swaps were as follows: March 31, 2020 December 31, 2019 Carrying Fair Carrying Fair (in thousands) Liabilities: Tranche B-2 Term Loan $ 434,773 $ 239,125 $ 441,500 $ 414,321 FILO Term Loan 273,898 231,786 266,814 265,851 Notes 156,427 148,606 154,675 148,488 Interest rate swaps 10,810 10,810 6,940 6,940

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares	The following table represents the Company's basic and dilutive weighted-average shares: Three months ended March 31, 2020 2019 (in thousands) Basic weighted average shares 83,897 83,510 Effect of dilutive stock-based compensation awards — — Diluted weighted average shares 83,897 83,510
Computations for Basic and Diluted Earnings per Common Share	The computations for basic and diluted loss per common share are as follows: Three months ended March 31, 2020 2019 (in thousands, except per share data) Loss per common share - Basic Net loss $ (200,086) $ (15,262) Cumulative undeclared convertible preferred stock dividend 5,195 3,716 Net loss attributable to common shareholders (205,281) (18,978) Weighted average common shares outstanding - basic 83,897 83,510 Loss per common share - basic $ (2.45) $ (0.23) Loss per common share - Diluted Net loss $ (200,086) $ (15,262) Cumulative undeclared convertible preferred stock dividends 5,195 3,716 Net loss attributable to common shareholders (205,281) (18,978) Weighted average common shares outstanding - diluted 83,897 83,510 Loss per common share - diluted $ (2.45) $ (0.23)

SEGMENTS (Tables)

SEGMENTS (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Schedule of Key Financial Information of the Segments	The following table represents key financial information for each of the Company's reportable segments: Three months ended March 31, 2020 2019 (in thousands) Revenue: U.S. and Canada $ 424,181 $ 489,157 International 33,545 40,923 Manufacturing / Wholesale: Intersegment revenues — 35,505 Third-party contract manufacturing — 15,783 Wholesale partner sales 14,855 18,901 Subtotal Manufacturing / Wholesale 14,855 70,189 Total reportable segment revenues 472,581 600,269 Elimination of intersegment revenues — (35,505) Total revenue $ 472,581 $ 564,764 Operating income: U.S. and Canada $ (131,200) $ 52,100 International (17,382) 14,050 Manufacturing / Wholesale 6,931 15,344 Total reportable segment operating income (141,651) 81,494 Corporate costs (24,835) (26,261) Loss on net asset exchange for the formation of the joint ventures (1,655) (19,514) Other 2,107 (237) Unallocated corporate costs, loss on net asset exchange and other (24,383) (46,012) Total operating (loss) income (166,034) 35,482 Interest expense, net 47,444 32,956 Loss on forward contracts for the issuance of convertible preferred stock — 16,787 Loss before income taxes $ (213,478) $ (14,261)

NATURE OF BUSINESS (Details)

NATURE OF BUSINESS (Details)	May 16, 2020USD ($)	Apr. 30, 2020USD ($)	Apr. 30, 2019USD ($)	Mar. 31, 2020USD ($)segmentcountry	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments | segment				3
Number of international countries in which franchise stores are located | country				50
Temporary Store Closure | Geographic Concentration Risk | US and Canada
Debt Instrument
Concentration risk percentage				30.00%
Tranche B-2 Term Loan, FILO Term Loan and Revolving Credit Facility
Debt Instrument
Long-term debt, gross				$ 738,700,000
Amortization of discount and debt issuance costs				12,400,000
Term Loan Facility | Amended Term Loan Facility Due March 2021
Debt Instrument
Minimum for notes repayment, refinanced, converted, discharged, or prepaid, For maturity date extension trigger				50,000,000
Term Loan Facility | Amended Term Loan Facility Due March 2021 | Tranche B-2
Debt Instrument
Borrowings outstanding				434,800,000	$ 434,800,000
Long-term debt, gross				434,773,000		$ 441,500,000
Term Loan Facility | Notes
Debt Instrument
Minimum for notes repayment, refinanced, converted, discharged, or prepaid, For maturity date extension trigger				50,000,000
Term Loan Facility | Notes | Forecast
Debt Instrument
Minimum for notes repayment, refinanced, converted, discharged, or prepaid, For maturity date extension trigger	$ 50,000,000
Term Loan Facility | Reduced Rate | Amended Term Loan Facility Due March 2021 | Tranche B-2
Debt Instrument
Payments for excess cash flows			$ 9,800,000
Term Loan Facility | Reduced Rate | Amended Term Loan Facility Due March 2021 | Tranche B-2 | Forecast
Debt Instrument
Payments for excess cash flows		$ 25,900,000
Notes | Notes
Debt Instrument
Borrowings outstanding				156,427,000	156,400,000	154,675,000
Long-term debt, gross				156,427,000		$ 154,675,000
Amortization of discount and debt issuance costs				217,000	$ 244,000
FILO Term Loan | Letter Of Credit
Debt Instrument
Line of credit outstanding				$ 4,500,000

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 22,648
Charged to costs and expenses	8,700
Ending balance	27,390
Vendor allowance
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	14,033
Charged to costs and expenses	5,439
Deduction	(6,707)
Ending balance	12,765
Trade account receivable allowance
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	8,615
Charged to costs and expenses	9,224
Deduction	(3,214)
Ending balance	14,625
COVID-19 Pandemic
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Charged to costs and expenses	8,700
COVID-19 Pandemic | Vendor allowance
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Charged to costs and expenses	$ 4,600

REVENUE - Disaggregation of Rev

REVENUE - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 472,581	$ 564,764
United States
Disaggregation of Revenue [Line Items]
Revenue	452,873	535,943
Foreign
Disaggregation of Revenue [Line Items]
Revenue	19,708	28,821
Manufacturing / Wholesale | Third-party contract manufacturing
Disaggregation of Revenue [Line Items]
Revenue	0	15,783
Manufacturing / Wholesale | Wholesale partner sales
Disaggregation of Revenue [Line Items]
Revenue	14,855	18,901
Operating Segment
Disaggregation of Revenue [Line Items]
Revenue	472,581	600,269
Operating Segment | U.S. and Canada
Disaggregation of Revenue [Line Items]
Revenue	424,181	489,157
Operating Segment | U.S. and Canada | Product Sales
Disaggregation of Revenue [Line Items]
Revenue	327,720	377,374
Operating Segment | U.S. and Canada | Protein
Disaggregation of Revenue [Line Items]
Revenue	73,808	80,257
Operating Segment | U.S. and Canada | Performance supplements
Disaggregation of Revenue [Line Items]
Revenue	67,992	74,778
Operating Segment | U.S. and Canada | Weight management
Disaggregation of Revenue [Line Items]
Revenue	20,516	30,779
Operating Segment | U.S. and Canada | Vitamins
Disaggregation of Revenue [Line Items]
Revenue	48,962	47,056
Operating Segment | U.S. and Canada | Herbs / Greens
Disaggregation of Revenue [Line Items]
Revenue	13,805	15,873
Operating Segment | U.S. and Canada | Wellness
Disaggregation of Revenue [Line Items]
Revenue	39,082	47,200
Operating Segment | U.S. and Canada | Health / Beauty
Disaggregation of Revenue [Line Items]
Revenue	39,485	46,388
Operating Segment | U.S. and Canada | Food / Drink
Disaggregation of Revenue [Line Items]
Revenue	19,199	28,243
Operating Segment | U.S. and Canada | General merchandise
Disaggregation of Revenue [Line Items]
Revenue	4,871	6,800
Operating Segment | U.S. and Canada | Wholesale sales to franchisees
Disaggregation of Revenue [Line Items]
Revenue	51,056	58,257
Operating Segment | U.S. and Canada | Royalties and franchise fees
Disaggregation of Revenue [Line Items]
Revenue	7,327	8,472
Operating Segment | U.S. and Canada | Sublease income
Disaggregation of Revenue [Line Items]
Revenue	10,242	10,976
Operating Segment | U.S. and Canada | Cooperative advertising and other franchise support fees
Disaggregation of Revenue [Line Items]
Revenue	4,408	5,067
Operating Segment | U.S. and Canada | Other
Disaggregation of Revenue [Line Items]
Revenue	23,428	29,011
Operating Segment | International
Disaggregation of Revenue [Line Items]
Revenue	33,545	40,923
Operating Segment | International | Wholesale sales to franchisees
Disaggregation of Revenue [Line Items]
Revenue	20,183	25,437
Operating Segment | International | Royalties and franchise fees
Disaggregation of Revenue [Line Items]
Revenue	6,508	6,202
Operating Segment | International | Other
Disaggregation of Revenue [Line Items]
Revenue	6,854	9,284
Operating Segment | Manufacturing / Wholesale
Disaggregation of Revenue [Line Items]
Revenue	14,855	70,189
Operating Segment | Manufacturing / Wholesale | Third-party contract manufacturing
Disaggregation of Revenue [Line Items]
Revenue	0	15,783
Operating Segment | Manufacturing / Wholesale | Wholesale partner sales
Disaggregation of Revenue [Line Items]
Revenue	14,855	18,901
Intersegment Eliminations
Disaggregation of Revenue [Line Items]
Revenue	0	(35,505)
Intersegment Eliminations | Manufacturing / Wholesale
Disaggregation of Revenue [Line Items]
Revenue	$ 0	$ (35,505)

REVENUE - Contract with Custome

REVENUE - Contract with Customer (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Deferred franchise and license fees
Contract liabilities:
Balance at Beginning of Period	$ 28,293	$ 33,464
Recognition of revenue included in beginning balance	(2,722)	(2,861)
Contract liability, net of revenue, recognized during the period	1,303	668
Balance at the End of Period	26,874	31,271
PRO Access and loyalty program points
Contract liabilities:
Balance at Beginning of Period	22,896	24,836
Recognition of revenue included in beginning balance	(11,879)	(12,423)
Contract liability, net of revenue, recognized during the period	11,096	12,863
Balance at the End of Period	22,113	25,276
Gift card liability (1)
Contract liabilities:
Balance at Beginning of Period	3,110	3,416
Recognition of revenue included in beginning balance	(1,367)	(1,523)
Contract liability, net of revenue, recognized during the period	207	181
Balance at the End of Period	$ 1,950	$ 2,074

REVENUE - Performance Obligatio

REVENUE - Performance Obligations (Details) $ in Millions	Mar. 31, 2020USD ($)
Revenue from Contract with Customer [Abstract]
Remaining performance obligation	$ 26.9
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Revenue from Contract with Customer [Abstract]
Remaining performance obligation	$ 6
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, period of recognition	12 months

INVENTORY (Details)

INVENTORY (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)segment	Dec. 31, 2019USD ($)
Inventory Disclosure [Abstract]
Finished product ready for sale	$ 367,402	$ 387,655
Inventory	367,402	$ 387,655
Inventory [Line Items]
Inventory reserve recorded	18,200
Charged to costs and expenses	8,700
Vendor allowance
Inventory [Line Items]
Charged to costs and expenses	$ 5,439
US and Canada | Temporary Store Closure | Geographic Concentration Risk
Inventory [Line Items]
Concentration risk percentage	30.00%
Number of stores | segment	1,100
U.S. and Canada
Inventory [Line Items]
Inventory reserve recorded	$ 17,800
Charged to costs and expenses	7,900
Manufacturing / Wholesale
Inventory [Line Items]
Inventory reserve recorded	$ 400

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT, NET (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)segment	Mar. 31, 2019USD ($)
Property, Plant and Equipment [Line Items]
Long-lived asset impairments and other store closing costs	$ 157,515	$ 0
Gain on sale of property	2,100
Company-Owned and Franchise Stores
Property, Plant and Equipment [Line Items]
Long-lived asset impairments and other store closing costs	40,300
Impairment of property and equipment	11,200
Right-of-use asset impairment	21,200
Store closing costs	$ 7,900
US and Canada | Temporary Store Closure | Geographic Concentration Risk
Property, Plant and Equipment [Line Items]
Number of stores | segment	1,100
Concentration risk percentage	30.00%

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 111,700
Goodwill impairment	$ 5,451
Intangible Assets | Minimum | Royalty Rate
Finite-Lived Intangible Assets [Line Items]
Measurement input	0
Intangible Assets | Minimum | Discount Rate
Finite-Lived Intangible Assets [Line Items]
Measurement input	0.20
Intangible Assets | Maximum | Royalty Rate
Finite-Lived Intangible Assets [Line Items]
Measurement input	0.03
Intangible Assets | Maximum | Discount Rate
Finite-Lived Intangible Assets [Line Items]
Measurement input	0.22
Goodwill | Income Approach
Finite-Lived Intangible Assets [Line Items]
Measurement input	0.50
Goodwill | Market Approach
Finite-Lived Intangible Assets [Line Items]
Measurement input	0.50
Goodwill | Minimum | Discount Rate
Finite-Lived Intangible Assets [Line Items]
Measurement input	0.20
Goodwill | Maximum | Discount Rate
Finite-Lived Intangible Assets [Line Items]
Measurement input	0.22
U.S. and Canada
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 88,600
International
Finite-Lived Intangible Assets [Line Items]
Goodwill impairment	$ 5,451

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Goodwill [Roll Forward]
Gross, beginning balance	$ 574,524
Goodwill, beginning balance	79,109
Accumulated impairments, beginning balance	(495,415)
Impairment	(5,451)
Translation effect of exchange rates	(106)
Total 2020 activity	(5,557)
Gross, ending balance	574,418
Accumulated impairments, ending balance	(500,866)
Goodwill, ending balance	73,552
US and Canada
Goodwill [Roll Forward]
Gross, beginning balance	389,895
Goodwill, beginning balance	9,251
Accumulated impairments, beginning balance	(380,644)
Impairment	0
Translation effect of exchange rates	0
Total 2020 activity	0
Gross, ending balance	389,895
Accumulated impairments, ending balance	(380,644)
Goodwill, ending balance	9,251
International
Goodwill [Roll Forward]
Gross, beginning balance	43,330
Goodwill, beginning balance	43,330
Accumulated impairments, beginning balance	0
Impairment	(5,451)
Translation effect of exchange rates	(106)
Total 2020 activity	(5,557)
Gross, ending balance	43,224
Accumulated impairments, ending balance	(5,451)
Goodwill, ending balance	37,773
Manufacturing / Wholesale
Goodwill [Roll Forward]
Gross, beginning balance	141,299
Goodwill, beginning balance	26,528
Accumulated impairments, beginning balance	(114,771)
Impairment	0
Translation effect of exchange rates	0
Total 2020 activity	0
Gross, ending balance	141,299
Accumulated impairments, ending balance	(114,771)
Goodwill, ending balance	$ 26,528

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Cost	$ 720,000	$ 720,000
Accumulated Amortization/Impairment	(531,000)	(419,280)
Total indefinite lived intangible assets	189,000	300,720
Accumulated Amortization/Impairment	(610,302)	(497,187)
Total definite lived intangible assets	69,891	71,298
Cost	869,193	869,205
Total intangible assets	$ 258,891	372,018
Franchise rights
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Life	3 years
Cost	$ 7,566	7,566
Accumulated Amortization/Impairment	(7,495)	(7,475)
Total definite lived intangible assets	$ 71	91
Retail agreements
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Life	30 years 3 months 18 days
Cost	$ 31,000	31,000
Accumulated Amortization/Impairment	(13,882)	(13,619)
Total definite lived intangible assets	$ 17,118	17,381
Franchise agreements
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Life	25 years
Cost	$ 70,000	70,000
Accumulated Amortization/Impairment	(36,517)	(35,817)
Total definite lived intangible assets	$ 33,483	34,183
Manufacturing agreements
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Life	25 years
Cost	$ 40,000	40,000
Accumulated Amortization/Impairment	(20,867)	(20,467)
Total definite lived intangible assets	$ 19,133	19,533
Other intangibles
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Life	6 years 9 months 18 days
Cost	$ 627	639
Accumulated Amortization/Impairment	(541)	(529)
Total definite lived intangible assets	$ 86	$ 110

DEBT _ INTEREST EXPENSE - Sched

DEBT / INTEREST EXPENSE - Schedule of Long-Term Debt (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Debt Instrument
Debt issuance costs	$ (76)		$ (424)
Total debt	895,022		862,565
Less: current debt	(895,022)		(180,566)
Long-term debt	0		681,999
Revolving Credit Facility
Debt Instrument
Long-term debt, gross	30,000		0
FILO Term Loan | Term Loan | FILO Asset-based Term Loan Facility
Debt Instrument
Long-term debt, gross	273,898		266,814
Debt discount	1,100		8,200
Convertible Senior Notes | Notes
Debt Instrument
Long-term debt, gross	156,427		154,675
Debt discount	314		524
Unamortized conversion feature	2,356	$ 3,900	3,898
Tranche B-2 | Term Loan Facility | Amended Term Loan Facility Due March 2021
Debt Instrument
Long-term debt, gross	434,773		441,500
Debt discount	$ 2,000		$ 7,000

DEBT _ INTEREST EXPENSE - Narra

DEBT / INTEREST EXPENSE - Narrative (Details) - USD ($)	May 16, 2020	Apr. 30, 2020	Apr. 30, 2019	Nov. 30, 2018	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Feb. 28, 2019
FILO Term Loan | Revolving Credit Facility
Debt Instrument
Maximum borrowing capacity					$ 100,000,000	$ 81,000,000		$ 100,000,000
Fee on outstanding balance					1.50%
Commitment fee on undrawn portion of revolving credit facility					0.375%
Potential increase of unused capacity fee					0.50%
Line of credit facility, remaining borrowing capacity					$ 19,900,000
Line of credit outstanding					30,000,000
Reduction to borrowing ability					$ 26,600,000
FILO Term Loan | Revolving Credit Facility | Minimum
Debt Instrument
Potential increase on fee on outstanding balance					0.25%
FILO Term Loan | Revolving Credit Facility | Maximum
Debt Instrument
Potential increase on fee on outstanding balance					0.50%
FILO Term Loan | Revolving Credit Facility | LIBOR
Debt Instrument
Basis spread on variable rate					1.50%
FILO Term Loan | Revolving Credit Facility | LIBOR | Minimum
Debt Instrument
Potential increase (decrease) on basis spread of variable rate					0.25%
FILO Term Loan | Revolving Credit Facility | LIBOR | Maximum
Debt Instrument
Potential increase (decrease) on basis spread of variable rate					0.50%
FILO Term Loan | Revolving Credit Facility | Prime
Debt Instrument
Basis spread on variable rate					0.50%
FILO Term Loan | Revolving Credit Facility | Prime | Minimum
Debt Instrument
Potential increase (decrease) on basis spread of variable rate					0.25%
FILO Term Loan | Revolving Credit Facility | Prime | Maximum
Debt Instrument
Potential increase (decrease) on basis spread of variable rate					0.50%
FILO Term Loan | Letter Of Credit
Debt Instrument
Line of credit outstanding					$ 4,500,000
FILO Asset-based Term Loan Facility | FILO Term Loan | Term Loan
Debt Instrument
Maximum borrowing capacity					$ 275,000,000
Effective interest rate					8.00%		8.80%
FILO Asset-based Term Loan Facility | FILO Term Loan | Term Loan | LIBOR
Debt Instrument
Basis spread on variable rate					7.00%
FILO Asset-based Term Loan Facility | FILO Term Loan | Term Loan | LIBOR | Minimum
Debt Instrument
Basis spread on variable rate					6.50%
FILO Asset-based Term Loan Facility | FILO Term Loan | Term Loan | Prime
Debt Instrument
Basis spread on variable rate					6.00%
FILO Asset-based Term Loan Facility | FILO Term Loan | Term Loan | Prime | Minimum
Debt Instrument
Basis spread on variable rate					5.50%
Amended Term Loan Facility Due March 2021 | Term Loan Facility
Debt Instrument
Minimum for notes repayment, refinanced, converted, discharged, or prepaid, For maturity date extension trigger					$ 50,000,000
Revolving Credit Facility | Term Loan
Debt Instrument
Effective interest rate					12.50%
Line of credit facility, remaining borrowing capacity					$ 12,500,000
Maximum net first lien leverage ratio					4.25
Minimum fixed charge coverage ratio					1
Revolving Credit Facility | Term Loan Facility
Debt Instrument
Effective interest rate					4.00%
Notes | Term Loan Facility
Debt Instrument
Minimum for notes repayment, refinanced, converted, discharged, or prepaid, For maturity date extension trigger					$ 50,000,000
Notes | Term Loan Facility | Forecast
Debt Instrument
Minimum for notes repayment, refinanced, converted, discharged, or prepaid, For maturity date extension trigger	$ 50,000,000
Notes | Convertible Senior Notes
Debt Instrument
Borrowings outstanding					156,427,000	156,400,000	$ 154,675,000
Amortization of discount and debt issuance costs					217,000	244,000
Tranche B-2 Term Loan, FILO Term Loan and Revolving Credit Facility
Debt Instrument
Amortization of discount and debt issuance costs					12,400,000
Tranche B-1
Debt Instrument
Payments on term loan facility					0	147,312,000
Tranche B-2
Debt Instrument
Payments on term loan facility					11,719,000	114,000,000
Tranche B-2 | Amended Term Loan Facility Due March 2021 | Term Loan Facility
Debt Instrument
Borrowings outstanding					434,800,000	$ 434,800,000
Annual principal payment					$ 43,000,000
Effective interest rate					10.10%		10.60%
Payments on term loan facility				$ 100,000,000
Tranche B-2 | Amended Term Loan Facility Due March 2021 | Term Loan Facility | Initial Rate
Debt Instrument
Mandatory prepayment, percent of excess cash flows					75.00%
Tranche B-2 | Amended Term Loan Facility Due March 2021 | Term Loan Facility | Reduced Rate
Debt Instrument
Mandatory prepayment, percent of excess cash flows					50.00%
Payments for excess cash flows			$ 9,800,000
Tranche B-2 | Amended Term Loan Facility Due March 2021 | Term Loan Facility | Reduced Rate | Forecast
Debt Instrument
Payments for excess cash flows		$ 25,900,000
Tranche B-2 | Amended Term Loan Facility Due March 2021 | Term Loan Facility | LIBOR
Debt Instrument
Basis spread on variable rate					8.75%
Tranche B-2 | Amended Term Loan Facility Due March 2021 | Term Loan Facility | LIBOR | Minimum
Debt Instrument
Basis spread on variable rate					8.25%
Tranche B-2 | Amended Term Loan Facility Due March 2021 | Term Loan Facility | LIBOR | Maximum
Debt Instrument
Basis spread on variable rate					9.25%
Tranche B-2 | Amended Term Loan Facility Due March 2021 | Term Loan Facility | Prime
Debt Instrument
Basis spread on variable rate					7.75%
Tranche B-2 | Amended Term Loan Facility Due March 2021 | Term Loan Facility | Prime | Minimum
Debt Instrument
Basis spread on variable rate					7.25%
Tranche B-2 | Amended Term Loan Facility Due March 2021 | Term Loan Facility | Prime | Maximum
Debt Instrument
Basis spread on variable rate					8.25%

DEBT _ INTEREST EXPENSE - Compo

DEBT / INTEREST EXPENSE - Components of Convertible Debt (Details) - Convertible Senior Notes - Notes - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Debt Instrument
Interest rate	1.50%
Liability component
Principal	$ 159,097		$ 159,097
Conversion feature	(2,356)	$ (3,900)	(3,898)
Discount related to debt issuance costs	(314)		(524)
Net carrying amount	$ 156,427	$ 156,400	$ 154,675

DEBT _ INTEREST EXPENSE - Inter

DEBT / INTEREST EXPENSE - Interest Rate Swaps (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2020USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 13, 2018USD ($)interest_rate_swap
Debt Instrument
Reclassified pre-tax loss	$ 10,810	$ 0
Interest rate swaps
Debt Instrument
Number of interest rate swaps | interest_rate_swap						2
Reclassified pre-tax loss	10,800
Interest Rate Swap One
Debt Instrument
Derivative, notional amount	$ 275,000					$ 275,000
Derivative floor interest rate						0.00%
Interest Rate Swap Two
Debt Instrument
Derivative, notional amount					$ 175,000	$ 225,000
Derivative floor interest rate						0.75%
Forecast | Interest Rate Swap Two
Debt Instrument
Derivative, notional amount			$ 75,000	$ 125,000

DEBT _ INTEREST EXPENSE - Sch_2

DEBT / INTEREST EXPENSE - Schedule of Derivative Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Derivative liability, current	$ 9,080	$ 5,013
Derivative liability, noncurrent	1,730	1,927
Derivative liability	$ 10,810	$ 6,940

DEBT _ INTEREST EXPENSE - Sch_3

DEBT / INTEREST EXPENSE - Schedule of Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Debt Instrument
Interest expense recognized on interest rate swap	$ 10,810	$ 0
Other	(90)	(9)
Interest expense, net	47,444	32,956
Senior Credit Facility
Debt Instrument
Amortization of discount and debt issuance costs	15,055	6,043
Interest expense	34,369	30,313
Senior Credit Facility | Revolving Credit Facility
Debt Instrument
Interest expense (excluding amortization)	149	123
Senior Credit Facility | FILO Term Loan | Term Loan
Debt Instrument
Interest expense (excluding amortization)	6,826	6,751
Notes | Convertible Senior Notes
Debt Instrument
Interest expense (excluding amortization)	596	707
Amortization of conversion feature	1,542	1,701
Amortization of discount and debt issuance costs	217	244
Interest expense	2,355	2,652
Tranche B-1 | Senior Credit Facility | Term Loan Facility
Debt Instrument
Interest expense (excluding amortization)	0	928
Tranche B-2 | Senior Credit Facility | Term Loan Facility
Debt Instrument
Interest expense (excluding amortization)	$ 12,339	$ 16,468

EQUITY METHOD INVESTMENTS - Nar

EQUITY METHOD INVESTMENTS - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended			12 Months Ended
	Mar. 31, 2019	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2019	Feb. 28, 2019
Schedule of Equity Method Investments [Line Items]
Revenue		$ 472,581		$ 564,764
Accounts receivable		6,500			$ 8,900
Other than temporary impairment		35,840			0
China Business | Disposal group, dispsed of by sale
Schedule of Equity Method Investments [Line Items]
Deconsolidation, gain (loss)				5,800
Nutra Manufacturing Business | Disposal group, dispsed of by sale
Schedule of Equity Method Investments [Line Items]
Deconsolidation, gain (loss)				(27,100)
JV Framework
Schedule of Equity Method Investments [Line Items]
Cash contributed				2,400
Finished goods purchased		36,400		21,000
Accounts payable		21,100			$ 11,700
Revenue		$ 3,800		2,200
Manufacturing JV
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership		32.00%
Proceeds for investment in newly formed joint venture	$ 99,200	$ 15,600	$ 101,000
Anticipated proceeds expected to be received	$ 75,000			$ 75,000
Anticipated proceeds expected to be received, period for recognition	4 years
Expected ownership percentage after all transactions	100.00%			100.00%
Annual proceeds for investment in new joint venture, amount per year	$ 18,800			$ 18,800
Gain (loss) on net asset exchange, pre-tax		(3,100)
Purchase price		18,800
Purchase price adjustment		$ 1,700
Manufacturing JV capital contribution
Schedule of Equity Method Investments [Line Items]
Capital contribution	$ 10,700
GNC Hong Kong Limited | JV Framework
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership	35.00%			35.00%		35.00%
Manufacturing JV | International Vitamin Corporation
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership	43.00%			43.00%
Purchase price adjustment			$ 1,800

EQUITY METHOD INVESTMENTS - Sum

EQUITY METHOD INVESTMENTS - Summary of Equity Method Investments (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]
Income from equity method investments	$ 4,618	$ 5,296
Distributions received from equity method investments	(3,856)	(3,856)
Manufacturing JV other-than-temporary impairment	(35,840)	0
Equity method investments	42,520	97,930
Manufacturing JV
Schedule of Equity Method Investments [Line Items]
Equity method investment, underlying equity in net assets	56,684	75,434
Manufacturing JV capital contribution
Schedule of Equity Method Investments [Line Items]
Equity method investment, underlying equity in net assets	10,714	10,714
HK JV and China JV
Schedule of Equity Method Investments [Line Items]
Equity method investment, underlying equity in net assets	$ 10,200	$ 10,342

FAIR VALUE MEASUREMENTS AND F_3

FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Actual and estimated fair values of the financial instruments
Derivative liability	$ 10,810	$ 6,940
Level 2 | Carrying Amount | Interest rate swaps
Actual and estimated fair values of the financial instruments
Derivative liability	10,810	6,940
Level 2 | Carrying Amount | FILO Asset-based Term Loan Facility | FILO Term Loan
Actual and estimated fair values of the financial instruments
Long-term debt	273,898	266,814
Level 2 | Carrying Amount | Notes | Notes
Actual and estimated fair values of the financial instruments
Long-term debt	156,427	154,675
Level 2 | Carrying Amount | Tranche B-2 | Amended Term Loan Facility Due March 2021 | Term Loan Facility
Actual and estimated fair values of the financial instruments
Long-term debt	434,773	441,500
Level 2 | Fair Value | Interest rate swaps
Actual and estimated fair values of the financial instruments
Derivative liability	10,810	6,940
Level 2 | Fair Value | FILO Asset-based Term Loan Facility | FILO Term Loan
Actual and estimated fair values of the financial instruments
Long-term debt	231,786	265,851
Level 2 | Fair Value | Notes | Notes
Actual and estimated fair values of the financial instruments
Long-term debt	148,606	148,488
Level 2 | Fair Value | Tranche B-2 | Amended Term Loan Facility Due March 2021 | Term Loan Facility
Actual and estimated fair values of the financial instruments
Long-term debt	$ 239,125	$ 414,321

CONTINGENCIES (Details)

CONTINGENCIES (Details)	Feb. 29, 2012action	Dec. 31, 2016	Mar. 31, 2020USD ($)lawsuit
Product Liability
Commitments and contingencies
Deductible/retention per claim			$ 4,000,000
Aggregate cap on retained loss			$ 10,000,000
DMAA Claims | Product Liability
Commitments and contingencies
Number of pending lawsuits in which company is named | lawsuit			27
Elizabeth Naranjo, California Wage and Break Claims
Commitments and contingencies
Number of claims filed | action	8
Violations of Oregon Unlawful Trade Practices Act
Commitments and contingencies
Loss contingency accrual			$ 0
Subpoena from Department of Justice Related to USP Labs
Commitments and contingencies
Term of settlement agreement		60 months

MEZZANINE EQUITY (Details)

MEZZANINE EQUITY (Details) $ / shares in Units, $ in Thousands	Feb. 13, 2019USD ($)shares	Jan. 02, 2019USD ($)shares	Nov. 09, 2018USD ($)shares	Nov. 08, 2018USD ($)tranche	Feb. 13, 2018USD ($)$ / sharesshares	Mar. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)$ / sharesshares
Temporary Equity [Line Items]
Preferred stock, shares authorized (in shares) | shares						60,000,000
Preferred Stock, par value (in dollars per share) | $ / shares						$ 0.001
Loss on forward contracts for the issuance of convertible preferred stock | $						$ 0	$ 16,787
Accumulated and unpaid dividends | $						$ 25,000		$ 19,800
Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock, par value (in dollars per share) | $ / shares						$ 1,000		$ 1,000
Convertible preferred stock, shares issued (in shares) | shares						299,950		299,950
Convertible preferred stock stated value | $						$ 300,000		$ 300,000
Series A Preferred Stock
Temporary Equity [Line Items]
Preferred Stock, par value (in dollars per share) | $ / shares						$ 1,000
Dividend rate						6.50%
SPA Amendment, Private Placement | Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock issued (in shares) | shares					299,950
Price per share (in dollars per share) | $ / shares					$ 1,000
Consideration received | $				$ 300,000	$ 300,000
Number of tranches | tranche				3
Shares converted (in shares) | shares					56,100,000
Initial conversion price (in dollars per share) | $ / shares					$ 5.35
SPA Amendment, Initial Issuance
Temporary Equity [Line Items]
Convertible preferred stock issued (in shares) | shares			100,000
Consideration received | $			$ 100,000
SPA Amendment, First Subsequent Issuance
Temporary Equity [Line Items]
Convertible preferred stock issued (in shares) | shares		50,000
Consideration received | $		$ 50,000
SPA Amendment, Second Subsequent Issuance
Temporary Equity [Line Items]
Convertible preferred stock issued (in shares) | shares	149,950
Consideration received | $	$ 150,000

EARNINGS PER SHARE - Schedule o

EARNINGS PER SHARE - Schedule of Weighted Average Number of Shares (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Basic weighted-average shares (in shares)	83,897	83,510
Effect of dilutive stock-based compensation awards (in shares)	0	0
Diluted weighted-average shares (in shares)	83,897	83,510

EARNINGS PER SHARE - Antidiluti

EARNINGS PER SHARE - Antidilutive and Contingently Issuable Shares (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antdilutive securities, entity in net loss position
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Antidilutive awards excluded from diluted EPS (in shares)	6.8	4
Convertible Preferred Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Antidilutive awards excluded from diluted EPS (in shares)	59.9
Convertible Debt Securities
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Antidilutive awards excluded from diluted EPS (in shares)	2.4

EARNINGS PER SHARE - Computatio

EARNINGS PER SHARE - Computations for Basic and Diluted Earnings per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Net loss	$ (200,086)	$ (15,262)
Cumulative undeclared convertible preferred stock dividend	5,195	3,716
Net loss attributable to common shareholders	$ (205,281)	$ (18,978)
Basic weighted-average shares (in shares)	83,897	83,510
Loss per common share - basic (in dollars per share)	$ (2.45)	$ (0.23)
Net loss	$ (200,086)	$ (15,262)
Cumulative undeclared convertible preferred stock dividends	5,195	3,716
Net loss attributable to common shareholders	$ (205,281)	$ (18,978)
Diluted weighted-average shares (in shares)	83,897	83,510
Loss per common share - diluted (in dollars per share)	$ (2.45)	$ (0.23)

SEGMENTS (Details)

SEGMENTS (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)segment	Mar. 31, 2019USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment	3
Expiring inventory and vendor receivable reserves	$ 22,800
Long-lived asset impairments and other store closing costs	157,515	$ 0
Charged to costs and expenses	8,700
Inventory reserve recorded	18,200
Revenue:
Revenue	472,581	564,764
Operating income:
Operating income	(166,034)	35,482
Loss on net asset exchange for the formation of the joint ventures	(1,655)	(19,514)
Interest expense, net	47,444	32,956
Loss on forward contracts for the issuance of convertible preferred stock	0	16,787
Loss before income from equity method investments and income taxes	(213,478)	(14,261)
U.S. and Canada
Segment Reporting Information [Line Items]
Expiring inventory and vendor receivable reserves	22,400
Long-lived asset impairments and other store closing costs	128,900
Charged to costs and expenses	7,900
Inventory reserve recorded	17,800
International
Segment Reporting Information [Line Items]
Long-lived asset impairments and other store closing costs	28,600
Charged to costs and expenses	800
Manufacturing / Wholesale
Segment Reporting Information [Line Items]
Expiring inventory and vendor receivable reserves	400
Inventory reserve recorded	400
Manufacturing / Wholesale | Third-party contract manufacturing
Revenue:
Revenue	0	15,783
Manufacturing / Wholesale | Wholesale partner sales
Revenue:
Revenue	14,855	18,901
Operating Segment
Revenue:
Revenue	472,581	600,269
Operating income:
Operating income	(141,651)	81,494
Operating Segment | U.S. and Canada
Revenue:
Revenue	424,181	489,157
Operating income:
Operating income	(131,200)	52,100
Operating Segment | International
Revenue:
Revenue	33,545	40,923
Operating income:
Operating income	(17,382)	14,050
Operating Segment | Manufacturing / Wholesale
Revenue:
Revenue	14,855	70,189
Operating income:
Operating income	6,931	15,344
Operating Segment | Manufacturing / Wholesale | Third-party contract manufacturing
Revenue:
Revenue	0	15,783
Operating Segment | Manufacturing / Wholesale | Wholesale partner sales
Revenue:
Revenue	14,855	18,901
Intersegment Eliminations
Revenue:
Revenue	0	(35,505)
Intersegment Eliminations | Manufacturing / Wholesale
Revenue:
Revenue	0	(35,505)
Corporate
Operating income:
Operating income	(24,383)	(46,012)
Corporate costs	(24,835)	(26,261)
Loss on net asset exchange for the formation of the joint ventures	(1,655)	(19,514)
Other	$ 2,107	$ (237)

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (53,035)	$ 1,956
Discrete tax benefit	10,800		$ 10,700
Partial valuation allowance that may not be realizable	27,600
Discrete permanent benefit, release of valuation allowance	4,800
Interest and penalties accrued related to unrecognized tax benefits	2,800		2,100
Valuation Allowance [Line Items]
Valuation allowance increase (decrease)	(4,800)		(4,800)
Federal Deferred Tax Assets, State NOL Carryforwards and Other State Tax Attributes
Valuation Allowance [Line Items]
Valuation allowance increase (decrease)	$ 27,600		$ 27,100

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) $ in Millions	May 06, 2020segment	Mar. 31, 2020segment	May 31, 2020USD ($)	Apr. 30, 2020USD ($)
US and Canada | Temporary Store Closure | Geographic Concentration Risk
Subsequent Event [Line Items]
Concentration risk percentage		30.00%
Number of stores | segment		1,100
Subsequent Event
Subsequent Event [Line Items]
Rent and occupancy payments withheld | $				$ 19
Subsequent Event | Forecast
Subsequent Event [Line Items]
Rent and occupancy payments withheld | $			$ 16
Subsequent Event | US and Canada | Temporary Store Closure | Geographic Concentration Risk
Subsequent Event [Line Items]
Concentration risk percentage	40.00%
Number of stores | segment	1,300

Uncategorized Items - gnc-20200

Label	Element	Value
Accounting Standards Update 2016-02 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (59,936,000)
Accounting Standards Update 2016-02 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (59,936,000)